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Abstract

Multi-drug resistance or MDR is a major impediment to the successful
administration of chemotherapy. Broadly defined, the term MDR applies to any
mechanism the cell uses to counter the effects of chemotherapeutic agents,

protecting the cell at once against the toxicity of many, structurally dissimilar
compounds. There are several routes to MDR for a cell, and they include

everything from decreasing intracellular drug concentrations to increasing rates
drug metabolism. The study presented here focuses on the role of drug
transporters in conferring drug resistance. MDR transporters are traditionally
thought to extrude cytotoxins from the cell at the plasma membrane, and they

thereby serve as a permeability barrier for drug entry into the cell. Several MDR
transporters have been cloned to date, but this study focuses on the functional

characterization of one of these proteins, the human multidrug resistance protein
or MRP 1.
MRP1, like other members of the MDR transporter family, is thought to
be expressed at the plasma membrane and decrease the intracellular accumulation
of many different chemotherapeutic compounds. Unlike other MDR transporters,
however, MRP 1 is thought to require reduced glutathione to enable the transport
of most of its chemotherapeutic substrates. Using a fluourescently tagged MRP1
protein, we make two novel demonstrations: that MRP1 can contribute to a drug
resistance phenotype from intracellular membranes, as well as from the plasma
membrane; and two, that MRP1 is active in the absence of glutathione.

Chapter 1 Introduction to Multidrug Resistance
Chapter One: A Brief Introduction to Multi-drug Resistance and the
A B C transporter family

1.1

Multi-drug Resistance Defined

Cellular multi-drug resistance or MDR is a significant obstacle to the
successful administration of chemotherapy. Broadly defined, the term MDR
applies to any mechanism the cell uses to counter the effects of chemotherapeutic
agents, protecting the cell at once against the toxicity of many, structurally
dissimilar compounds. There are several routes to MDR for a cell, and they
include everything from decreasing intracellular drug concentrations to increasing
rates of drug metabolism (see two recent reviews (Gottesman, 2002;Gottesman et
al, 2002)). I will briefly give an overview of the cellular mechanisms of
acquiring drug resistance, organizing the discussion under two general
subheadings: one, diminishing drug availability to cellular targets, and two,
altering drug sensitivity.
Decreasing the availability of drugs to their cellular targets can occur
simply by reducing the rates of drug entry. For drugs that enter cells by passive
diffusion, for example, structural changes at or near the plasma membrane can
alter rates of drug entry. Recent research into drug resistance in polarized
epithelial cells, for example, suggests that barriers to drug diffusion are created in
an "entrance compartment" by micro-villi and an associated actin cytoskeleton
(Lange and Gartzke, 2001). For those drugs that enter cells by utilizing existing
cellular machinery, decreases in drug uptake can occur either as a result of
changes in the endocytic pathway or in plasma membrane receptors. Resistance
to the anti-folate drug methotrexate, for example, often occurs as a result of
mutations in the two transporters responsible for folate uptake, transporters co-
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opted by the drug to enter the cell (for a review, see Cancer, Principles
and Practices of Oncology). Decreased drug presentation can also occur if the
drug is sequestered away from cellular targets once it has entered the cell. The
chemotherapeutic doxorubicin, for instance, accumulates in the lysosomes of drug
resistant cells, and is thus kept from the nucleus, where it is known to induce
apoptosis by damaging DNA (Schindler et ai, 1996;Hurwitz et al, 1997).
Finally, drugs can be less available at their cellular targets because they are
effluxed from the cell upon entry. Drug efflux pumps like the well studied Pglycoprotein are expressed at the plasma membrane and actively extrude
chemotherapeutics in an ATP-requiring transport event. Transporters like Pglycoprotein will be the subject of this study and will be discussed subsequently
in further detail.
Under the second subheading of acquiring MDR, we find all the methods
available to the cell to reduce cellular sensitivity to MDR agents. Increasing rates
of DNA repair, for example, or inhibiting apoptosis, both increase survival rates
in response to chemotherapeutics. Drugs can also be metabolized, thereby
altering their toxicity. Cisplatin resistance, for example, is associated with
increases in the expression of the gene encoding glutathione-S-transferase
71 (GST). Moreover, GST-mediated glutathione conjugation is frequently
associated with drug resistance to alkylating compounds like melphalan
(Yokomizo et al, 1995), as well as many other electrophilic chemotherapeutics
(Morrow et al, 1998). Other detoxification pathways exist, and are broadly
classified under two general categories: Phase I detoxification, in which a
functional group is added or exposed (usually via a cytochrome P-450 enzyme) or
Phase II detoxification, in which drugs undergo conjugation reactions via
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glutathionation, sulfonation, acetylation or methylation (see Cancer,
Principles and Practices of Oncology). Finally, cells can become MDR by
altering their sensitivity to the anti-proliferative nature of chemotherapeutic
agents, with less stringent cell cycle regulation, for example.

1.2 ABC transporters and Multi-drug resistance
To date, 48 human transporters belonging to the ATP-binding cassette
(ABC) family of proteins have been identified (Muller, 2003), and a number of
them have been implicated in the development of multi-drug resistance. These
transporters confer drug resistance by actively extruding chemotherapeutic
compounds from the cell, in an ATP-dependent manner. The first and probably
most well characterized ABC protein involved in acquiring MDR is Pglycoprotein, encoded by the multidrug resistance 1 (MDR1) gene. Overexpression of the cDNA encoding P-glycoprotein is sufficient to confer drug

resistance to many structurally unrelated cytotoxins, including those administere
in chemotherapy, like the anthracyclines, the vinca-alkaloids, and colchicine
(Gros et al, 1986;Chen and Simon, 2000). P-glycoprotein (Pgp) is a 170-kDa
protein, expressed in the apical membrane of polarized cells, whose expression
can be inversely correlated with the successful administration of chemotherapy
(Chan et al, 1991). Structurally, Pgp and other members of the ABC family
generally consist of a core of 12 transmembrane domains and two nucleotide
binding domains, although there are some notable exceptions (Borst and Elferink,
2002). The breast cancer resistance protein or BCRP, for example, is a half
transporter, and consists of only 6 transmembrane domains and one nucleotide
binding domain. The multi-drug resistance protein 1, as well as other members of

Chapter 1 Introduction to Multidrug Resistance

5

the MRP family, have a core structure similar to Pgp, with a 280 amino
acid N-terminal extension (Bakos et al, 1998). However, what these MDRconferring ABC proteins all share is the ability to significantly reduce the
intracellular concentration of many structurally unrelated compounds when overexpressed at the cell surface.

1.3 MRP1
Human MRP1, or the multidrug associated protein 1, is a 190-kDa
member of the ABC family of transporters. The gene encoding MRP1 is to be
found on chromosome 16; it spans 200 kb minimally and includes 31 exons, as
well as multiple class 0 introns (Grant et al, 1997). As its name suggests, the
protein is thought to be responsible for conferring multidrug resistance in a
variety of cancers and has, like Pgp, become a major obstacle to the successful
administration of chemotherapy. First cloned in 1992 from a daunorubicin

resistant lung cancer cell line (Cole et al, 1992), MRP1 has since been associated
with increased resistance to doxorubicin, vincristine, VP16, and colchicine.
MRP1 is expressed ubiquitously throughout the body (Borst et al, 2000), and
MRP1 mRNA has been found in a large variety of tumor types (Hipfner et al,
1999). Moreover, increased expression of the transporter has been shown to
correlate with poor clinical outcomes (Hipfner et al, 1999).
Physiologically, MRP1 is thought to extrude the cysteinyl leukotriene
LTC4 from the cell, as well as other conjugated organic anions. Its ability to
transport LTC4 has suggested a role for MRP1 in mediating the migration of

dendritic cells to the lymph nodes, as extrusion of LTC4 in these cells is necess
for chemotaxis to the chemokine CCL19 (Robbiani et al, 2000). Its transport of
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LTC4 has also implicated MRP1 in regulating inflammation in tissues, as
MRP1 null mice were deficient in both LTC4 transport, as well as LTC4dependent inflammatory responses (Wijnholds et al, 1997). Additionally,
MRP 1-mediated LTC4 transport has been found to correlate with increased

sensitivity to Streptococcus pneumoniae, as increased intracellular concentratio
of LTC4 negatively regulate LTC4 biosynthesis, and thereby increase production
of another cysteinyl leukotriene LTB4, an important elicitor of microbiocidal
responses in phagocytic cells (Schultz et al, 2001).
Despite these physiological roles, mrpl null mice are viable, fertile, and
show no developmental phenotypes or discernable changes in body or organ
morphology (Wijnholds et al, 1997). However, these mice have substantially
increased sensitivities to MDR drugs like VP16 and vincristine (the latter only
isolated bone marrow derived mast cells). As a result of exposure to etoposidephosphate, mrpl null mice show extensive damage in the oropharyngeal mucosal

layer, the testicular tubules, and the choroid plexus epithelium, suggesting that
protein actively protects against xenobiotic agents in these tissues (Wijnholds
al, 1998;Wijnholds et al, 2000). Mouse mrpl is also thought to contribute to the
blood brain drug permeability barrier (Wijnholds et al, 2000).

1.4 Contextualizing our present study
Despite these many and substantial advances in our understanding of
MRP1 activity, both in normal and in patho-physiology, many avenues still
remain open for MRP1 studies. Previous biochemical and whole cell
investigations of MRP 1, for example, have produced a number of inconsistent
reports of MRP 1 substrate specificity and activity in general. Some in vivo
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studies have found MRP1 to be functional in intracellular compartments
(Tommasini et al, 1996), while others have seen MRP1 active primarily at the
plasma membrane. Some studies have suggested MRP1 to be active against
mitoxantrone, cadmium, vinblastine, and colchicine (Tommasini et al, 1996),
while others have found MRP1 to confer no increased resistance to these
compounds. Some of these inconsistencies may be due to the different cell lines
used to study MRP1; many no doubt are due to the culture conditions used to
model in vivo MRP1 activity. Cells are either continuously cultured in
chemotherapeutic agents or selected in antibiotics to ensure MRP1 expression.
These culture conditions have been shown to result in massive physiological
changes in the cell, including the up-regulation of DNA repair enzymes, the
down-regulation of apoptotic machinery, resulting in the generation of
multifactorial drug resistance (Chen and Simon, 2000). Therefore, the changes
induced by drug selection could not be distinguished from the effect of MRP 1
expression.
For all these reasons, we have developed a means of studying MRP1
activity in whole cells without protracted drug selection. We have created a GFP
fusion construct which tags the C terminus of MRP 1 and permits easy
identification of MRP 1 expression in cells. The fusion protein additionally allows
us to correlate degrees of MRP 1 expression with GFP fluorescence, and thereby
makes direct studies of MRP 1 activity possible. By comparing cells transiently
transfected with the MRP 1-EGFP fusion construct to their non-transfected
counterparts, we can assess the immediate effect that MRP1 introduction has on a
cell's drug resistance properties. Transient transfection with the MRP 1-EGFP
fusion construct obviates the need for protracted propagation in antibiotics and
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product guidelines. To increase the transfection efficiencies of primary
and embryonic stem cell lines, endotoxin free DNA was used; endotoxin-free
DNA was purified using the Endo-free plasmid purification kit from Qiagen.

2.2 DNA constructs.
The plasmid encoding synaptotagminVII-ECFP was a gift from Norma
Andrews, Yale University, New Haven, Connecticut (Litman et al, 2000). The
plasmid encoding ECFP-CFTR was a gift of David Gadsby, Rockefeller
University, New York, New York. The pEYFP-ER and the pEYFP-Golgi vectors
were purchased from BD Biosciences Clontech, Palo Alto, California.
The construction of the pMDRl-ECFP plasmid has been previously
described (Chen and Simon, 2000). Briefly, the MDR1-EGFP fusion vector was

made using site-directed mutagenesis to replace the 3' stop codon with a Sail sit
The MDR1 open reading frame was then inserted into pEGFP-Nl (Clontech).
The EGFP coding region was then excised and replaced with ECFP, using Apal
and BsrGI restriction enzymes.
BCRP cDNA was a generous gift of Doug Ross, University of Maryland,
Baltimore, Maryland (Doyle et al, 1998); it was subcloned into the EGFPcl
plasmid (Clontech) between the EcoRI and Xhol sites. The pECFP-BCRP
plasmid was made by replacing the EGFP coding sequence with the sequence of
ECFP.
Human MRP1 cDNA was obtained in the cloning vector pGEM-1 lZf (gift
of Gary Kruh, Fox Chase). To generate an expression plasmid for wild-type
MRP1, designated pMRPl, MRP1 cDNA was subcloned between the Sacl and
Xbal sites of pEGFP-Nl (Clontech, Palo Alto, CA), a step that excised the EGFP
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coding sequence and created a pEGFP-Nl-backbone plasmid with
MRP1 placed under the control of the CMV promoter. To generate the MRP1EGFP fusion protein, standard mutagenesis techniques were used on pMRPl to
replace the MRP1 stop codon with an Agel site, the site at which GFP was
introduced. pMRPl-ECFP and pMRPl-EYFP were created by replacing EGFP
with ECFP or EYFP (Clontech).

2.3 Western blot analysis
MRP1 and MRP 1-EGFP transfected cells were dissociated with Cell
Stripper (Cellgro) and solubilized with 1% Triton X-100. The nuclear debris was
removed by a low speed centrifugation and the supernatant was resolved on a 420% gradient gel, using SDS PAGE. After electro-transfer onto a membrane
(Amersham Pharmacia Biotech, Piscataway, NJ) using a semi-dry electro-blotter,
proteins were immunoblotted with either the MRPrl anti-MRP 1 rat monoclonal
antibody (Alexis Biochemicals, San Diego, CA) and an alkaline phosphatase

conjugated anti-rat IgG antibody (Sigma) or directly with the alkaline phosphatas
conjugated Living Colors Peptide Antibody (Clontech).

2.4 Fluorescence microscopy
Cells were observed by fluorescent microscopy on fibronectin-coated
(Sigma) glass bottom culture dishes (MatTek, Ashland, MA). Wide field
fluorescence microscopy was performed with an IX-70 Olympus microscope
using a 1.4 N.A. X60 oil-immersion objective, and an ORCA cooled CCD camera
(Hamamatsu Photonics, Hamamatsu City, Japan) as previously described (Chen
and Simon, 2000). Wide field fluorescence microscopy with deconvolution was
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performed using a DeltaVision deconvolution microscope with a 1.4
N.A. oil-immersion 60X objective. The following excitation and emission filters
were used for wide-field fluorescent microscopy: CFP: Xex = 400-430 nm, Am =
460-500 nm; GFP: Ax - 480-490 nm, Xem = 500-550 nm; TMRE: Ax = 530-560
nm, Xem = 570-650 nm. Confocal microscopy was performed on either an upright
Axioplan 2 microscope or an inverted Axiovert 100 microscope, each with an
LSM 510 confocal attachment (Carl Zeiss, Thornwood, NY), using a 1.2 N.A.
water-immersion 63X objective. The following excitation laser lines and emission
filters were used: GFP: ^ex = 488 nm, Am = 500-530 nm; daunorubicin,
doxorubicin: Ax = 488 nm, Am = 580 nm long pass (LP); and mitoxantrone: Ax =
633 nm, Am - 650 nm LP.
Fluorescent images were analyzed using MetaMorph software (Universal
Imaging, Downington, Pennsylvania). To quantify fluorescence intensities on a

cell-by-cell basis, bright field images were used to acquire the cell boundary, a
MetaMorph software was used to calculate the average intensity within the
cellular boundary for each fluorophore. The mean of these averages was
calculated, along with the standard error. Data was collated and graphed using
software from Sigma Plot (SPSS Science, Chicago, IL). The degree to which
different fluorescent markers were said to correlate was determined by the

correlation co-efficient for any two given fluorophores, where the correlation co
efficient is an expression of the degree to which the pixel intensities of two
different fluorophores deviate from each other for a given area within a
micrograph. Correlation co-efficient calculations were performed using
MetaMorph software.
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2.5 Activity Assays and Fluorescence Quantification
2.5.1 Fluorescent chemotherapeutic reagents
Tetramethyl rhodamine ester or TMRE was purchased from Molecular
Probes, Eugene, Oregon. Mitoxantrone was purchased from Sigma. Doxorubicin
and daunorubicin were purchased from Calbiochem, La Jolla, California.
MRP1, BCRP, and Pgp activity assays were conducted similarly. 24-48

hours after transfection, cells expressing fluorescent conjugates of the transpor
of interest were washed in HHBSS, incubated in either 50 nM TMRE, 1-10 uM
daunorubicin, 1-1 OuM doxorubicin, or 1-10 uM mitoxantrone for 15 minutes in a
5% pC02 incubator, and observed by fluorescent microscopy. All
chemotherapeutic reagents, with the exception of TMRE, were washed out prior
to observation.
2.5.2 Non-fluorescent chemotherapeutic reagents
Vincristine, vinblastine, and colchicine were purchased from Calbiochem.
Cells expressing fluorescent conjugates of the transporters of interest were
washed in HHBSS, incubated in 100-600nM vincristine, 100-600nM vinblastine,
or 2uM colchine for different time intervals in a 5% C02 incubator, then washed
in HHBSS, and subsequently fixed and immunostained to visualize the

microtubule cytoskeleton. To visualize microtubules, cells were washed in chilled
phosphate buffered saline (PBS), permeabilized with ice-cold methanol for 10
min at 20 °C, washed in ice cold PBS, and immuno-labeled with Cy3-labeled anti(3 tubulin antibody (Sigma) according to manufacturer's instructions.
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2.5.3 Assays for speculated MDR modulators
Verapamil was used to inhibit MRP1 transport activity at 50uM. Buthione
sulfoximine (BSO) was purchased from Sigma. Cells were incubated in 25|iM
BSO for 24 hours prior to assays of MDR transport or intracellular glutathione
concentration, and was present during all transport assays.

2.6 Immunocytochemistry.
For fixation, cells were washed with chilled phosphate buffered saline
(PBS), permeabilized with ice-cold methanol for 10 min at 20 °C, and rinsed
twice with cold PBS. To detect MRP1 or cathepsin D, fixed cells were then
incubated with the anti-MRP 1 antibody MRPlrl at 1:200 or with the anticathepsin D antibody cathepsin D (Ab-2) (Oncogene Research Products, San
Diego, California) at 1:20 for one hour. Cells were subsequently washed and
incubated for one hour in anti-rat Alexa594 (Molecular Probes) 1:1,000 for MRP1
or anti-rabbit fluorescein for cathepsin D imaging.
To visualize microtubules, MRP1-CFP transfected cells were fixed in 95%
ethanol for 10 minutes at -20°C, washed in ice cold PBS, and immuno-labeled
with Cy3-labeled anti-p tubulin antibody (Sigma) according to manufacturer's
instructions.

2.7 Crosslinking
BM[PEO]4 stock was prepared at 28mM in water and used at a hundred
fold dilution in Hanks buffered saline solution with lOmM Hepes, pH 7.3
(HHBSS). Cells were exposed to the reagent at 37 °C for 10 minutes. The
crosslinking reaction was quenched with 50mM L-cysteine in HHBSS (quenching
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buffer) for 5 mintues at room temperature. Cells were subsequently
washed with HHBSS and then assayed for MRP1 activity. Crosslinking with
BMH was performed with a 90mM DMSO stock used at 1/1000X. Once again,
cells were exposed to BMH for 10 minutes at 37 °C, then resuspended in
quenching buffer for 5 minutes at room temperature, washed in HHBSS, and then
assayed for MRP 1 activity.

2.8 Fluorescent labeling of subcellular compartments.
In order to label the recycling endosome, cells were incubated with cy3transferrin, as previously described (Lampson et al, 2001). In order to label the
lysosomes, cells were transfected with synaptotagmin VII-ECFP or were probed
with an anti-cathepsin D antibody. Additionally, Texas Red dextrans were chased
into the lysosomes as follows: cells were incubated in dextrans for 1 hour at 37
°C, washed in culture medium, washed again lhour later, and then allowed to
remain in culture medium for 8-12 hours.

2.9 Glutathione assays.
Glutathione assays were performed using the FluoReporter
Glutathione/Glutathione S-Transferase Assay Kit from Molecular Probes
(Eugene, Oregon) according to manufacturer's instructions. Briefly, confluent
cells were dissociated with Cell Stripper (Cellgro) and lysed in a solution
containing 1% Triton X-100, protease inhibitor and ImM EDTA. Cell lysates

were then incubated in reaction buffer with kit-provided glutathione S-transfera
enzyme and pentafluorobenzyl fluorescein for 30 minutes in a 37°C water bath.
Reaction products were then assessed for fluorescent glutathione adducts using
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thin layer chromotagraphy (TLC). Samples were dotted onto TLC
silica gel 60 F254 plates (EM Science, Merk, Darmstadt, Germany), and then these
plates were placed in a TLC chamber containing 60% 1-butanol, 20% methanol,
and 20% water. Fluorescent adducts were detected and analyzed using standard
techniques. This assay is advertised to be sensitive to within lOuM GSH.

2.10 Flow cytometry
Flow cytometry was performed on a FACSort (Becton Dickinson, San

Jose, CA). Adherent cells were non-enzymatically dissociated using Cell Stripper,
resuspended in Opti-MEM with fluorescent drugs and incubated at 37 °C for 30

min, and stored on ice until sample acquisition (not more than 30 min). The cells
were harvested and resuspended in ice-cold PBS with a DNA stain to label dead
cells [either 10 nM TOTO-3 iodide (Molecular Probes) or 1 uM propidium iodide
(Sigma)] immediately before data acquisition. The lasers and filters used were:
GFP: Ax = 488 nm, A,em = 500-520 nm; daunorubicin, doxorubicin, TMRE,
propidium iodide: Ax = 488 nm, A,em = 564-606 nm; and mitoxantrone, TOTO-3
Ax = 633 nm, X em = 650 nm LP.
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3 Chapter 3 Assessments of MRP1-EGFP expression and activity

3.1 Generation of MRP1-EGFP
In the first chapter, we discussed some of the different approaches

available to the study of multiple drug resistance, and particularly, that mediat
by MRPL The method that we have chosen to employ, fluorescence-based in

vivo analysis of protein function, requires fluorescent labeling of both MRP1 and
its drug substrates. A number of MRP 1 substrates are naturally fluorescent and

therefore could be used to monitor the drug transport activity of the protein. To
label MRP1 itself with a fluorescent tag, we chose to add the enhanced green
fluorescent protein to the C-terminus of MRP 1 (Fig. 3-1). Using site-directed
mutagenesis, we replaced the stop codon of the MRP1 cDNA with a restriction
site that facilitated the addition of the enhanced green fluorescent protein or
(see Materials and Methods). Once the EGFP tag was added to the C-terminus of
MRP1, substitutions of the EGFP coding region were made which replaced the
EGFP with the enhanced cyan fluorescent protein (ECFP), the enhanced yellow
fluorescent protein (EYFP), or Ds Red.

3.2 Expressing the construct in HeLa cells
To determine whether the protein would be functional with a fluorescent
tag, we transfected the MRP 1-EGFP cDNA into HeLa cells, a cell line derived
from a human, cervical adenocarcinoma. This cell line is easily transfected,

adheres well to fibronectin-coated glass cover-slips, and, when adherent, exhibit
a flattened morphology that makes it a good choice for epi-fluorescent
microscopy. Although HeLa cells do express MRP1 endogenously, this
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expression is not sufficient to confer drug resistance. For instance, nontransfected HeLa cells are 5 to 15 fold more sensitive to doxorubicin,
daunorubicin, vincristine, and VP16 than HeLa cells transfected with, and overexpressing, MRP 1 (Cole et al, 1994). In our own investigations of nontransfected HeLa cells, we found that endogenously expressed MRP1 migrated as
a doublet near the 250 kDa protein marker, a finding in keeping with the 190kDa
molecular weight reported for MRP1 (Fig. 3-2, a). A similar MRP1 doublet has
been seen in cells transfected with MRP1 cDNA reference, and this doublet most
probably represents different glycosylation states of the protein (Bakos et al,
1996).
Immunocytochemistry revealed the protein to be at the plasma membrane,
and in another sub-cellular compartment, a distribution that has also been
previously reported for the protein (Chang et al, 1997). (Fig. 3-2, b). The sub-

cellular distribution of the protein will be the subject of future chapters. Desp
this endogenous expression of MRP 1, the HeLa cell line remains sensitive to the
addition of chemotherapeutics, and exogenous over-expression of the protein
confers drug resistance and supports enhanced transport of various
chemotherapeutic agents (Grant et al, 1994). Of course, drug resistance is a
relative term, and the sensitivity of non-transfected HeLa cells is simply a
comparative assessment of drug toxicity. Endogenous MRP1 is most probably

functional in HeLa cells, and the over-expression of this protein confers increas

drug resistance. Moreover, because the HeLa cell line has been used frequently to

examine the effects of MRP 1 over-expression, both in vivo and in vitro, the cell

line was an ideal starting point for our own investigations of MRP1-ECFP activity

(Leier et al, 1994;Cole et al, 1994;Grant et al, 1994;Leier et al, 1996;Loe et al
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1996a;Loe et al, 1996b;Ito et al, 2001;Qian et al, 2001;Rybczynska et
al, 2001).

3.3 MRP1-EGFP is expressed in cells as a full-length protein
HeLa cells were therefore transfected with the MRP 1-EGFP construct and

examined first for protein expression. As with any fluorescent protein conjugate,
we had to confirm that the observed fluorescence was from the EGFP-MRP1

fusion protein rather than a proteolytically cleaved fragment which contained jus
EGFP. In this way, we could ensure that we would not mistake free EGFP or

partially proteolyzed protein for a full-length construct. We used two methods to
ascertain whether the EGFP tag could be a reliable marker for MRP1:
immunocytochemistry and Western blot. For the latter, cells were first
transfected with MRP 1-EGFP or wild-type MRP1, lysed, and then probed on
immunoblots for the expression of MRP1 and EGFP (Fig. 3-3, a-b). Once again,
over-expressed wild-type MRP1 was found to run as a doublet, near the 250-kDa
marker, much like endogenously expressed MRP1 did (compare Fig 3-2 a, and
Fig. 3-3, a, left lane). Likewise, the MRP 1-EGFP protein band was also found to

run as a doublet, but its electrophoretic mobility was slightly retarded relative
wild-type MRP1, a finding in keeping with the addition of a 27-kDa EGFP tag to
MRP1 (Fig. 3-3, a, right lane). Protein fragments were not detectable in either

lane, suggesting that there was very little protein degradation of either MRP1 or
MRP 1-EGFP. Probing cell lysates with an anti-EGFP antibody (an anti-Living
colors peptide antibody) yielded similar results: no protein fragments were
detectable in MRP 1-EGFP transfected cells, and MRP 1-EGFP ran as a doublet
near a 250-kDa protein marker (Fig. 3-3, b).
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Immunocytochemistry of MRP 1-EGFP transfected cells also
suggested that the EGFP fluorescent marker remained closely associated with
MRPL We found nearly identical fluorescence distributions for EGFP
fluorescence as for immunofluorescence against MRP1, when cells were
transfected with MRP 1-EGFP, and then fixed and labeled with fluorescent antiMRP 1 secondary antibodies (Fig. 3-3, c-f). There was no evidence of free EGFP,
for there was no EGFP fluorescence in the nucleus of MRP 1 -EGFP transfected

cells (Fig. 3-3, c, truncated arrow), nor was there any cytosolic fluorescence. Fr
EGFP is known to accumulate in the nucleus and the cytosol when it is expressed
in cells. However, EGFP fluorescence in MRP 1-EGFP transfected cells remained
primarily at the surface of the cell on the plasma membrane and in a region
adjacent to the nucleus, a pattern very similar to that seen with endogenouslyexpressed, wild-type MRP1 (Fig. 3-2, b). In addition, the anti-MRP 1 label in
MRP 1-EGFP expressing cells mirrored EGFP fluorescence: the MRP1 label was
also at the plasma membrane and adjacent to the nucleus (Fig. 3-3, d). The
merge of anti-MRP 1 fluorescence (red) and EGFP fluorescence (green) revealed

the extent of their co-localization; the two signals overlapped closely and creat
a more or less yellow image (Fig. 3-3, e). A line-scan of the merged image
demonstrated the extent to which the two fluorophores had similar distributions
across a given cell (Fig. 3-3, f). Further investigations of the sub-cellular
localization of MRP 1-ECFP were conducted, but discussion of this will be saved
for the following chapter. For now, it is sufficient for us to note that two
independent assays suggested that the N and C terminii of MRP 1-EGFP were
always expressed in conjunction, the amino-terminal region of MRP 1 being
identified by the MRPrl antibody (at amino acids 238-247 (Flens et al,
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1994;Chang et al, 1997)) and the C-terminus by EGFP fluorescence.
Thus, it was most likely that MRP 1-EGFP was being expressed in cells as a full
length protein.

3.4 Fluorescent MRP1 activity assays
We now wanted to transfect the fluorescent MRP1 construct into cells and

assay its transport activity. Our first activity assay was with TMRE, a fluoresce
MRP1 substrate that enters the mitochondria of living cells. Because the
fluorescence spectra of TMRE overlaps that of EGFP, we chose to transfect cells
with MRP 1-ECFP for our initial assessments of protein activity. Transient

transfection with MRP 1-ECFP resulted in a mixed population of cells: cells that

expressed MRP 1-ECFP to various degrees (high to low), as well as cells that did

not express the protein at all. The latter population of cells served as an inte
control. Relative to this control, the expression of MRP 1-ECFP would result in
decreased drug accumulation if the protein were active. Cells that expressed the
fusion protein would be easily detectable by their ECFP fluorescence; if ECFPpositive cells consistently showed decreased TMRE fluorescence, we would judge
the transporter to be functional against this substrate. When MRP 1-ECFP
transfected cells were loaded with TMRE, we found that the protein substantially
reduced the intracellular accumulation of TMRE at steady-state (Fig. 3-4). In a
field of transfected cells loaded with TMRE, the cell expressing MRP 1-ECFP and
visible by ECFP fluorescence (Fig. 3-4, a) was not visible under TMRE

fluorescence (Fig. 3-4, b). Only the non-MRP 1 expressing cells in the field, th
not detectable by ECFP fluorescence, were illuminated under TMRE fluorescence
(Fig. 3-4, b). The merge of the two fluorescent images made this drug
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accumulation pattern clear: where there was ECFP fluorescence (green),
there was no TMRE fluorescence (red), and where there was TMRE fluorescence,
there was no ECFP fluorescence (Fig. 3-4, c).
Because TMRE is a live stain dye, we wanted to be sure that the absence
of TMRE fluorescence in MRP 1-ECFP expressing cells was not the result of
compromised cell viability. We chose therefore to pre-incubate cells with
verapamil, a known inhibitor of MRP 1 activity, and then assay its effect on
TMRE accumulation in transfected cells. If MRP 1-ECFP expression were

simply causing cell death, then the addition of verapamil should have no effect o
TMRE exclusion in these cells; on the other hand, if TMRE exclusion in MRP1ECFP expressing cells had been the result of MRP 1-mediated transport, then the
inhibition of MRP 1 transport activity by verapamil would promote TMRE
accumulation in these cells. When MRP 1-ECFP transfected cells were preincubated in verapamil, we saw that MRP 1-ECFP expressing cells (Fig. 3-4, d)
were no longer able to exclude TMRE (Fig. 3-4, e-f), while non-expressing cells
still accumulated the drug (Fig. 3-4, e-f). This experiment suggested active
transport of TMRE by MRP 1-ECFP.
Once we had established that MRP 1-EGFP was both fully expressed and

functional, we could now test the activity of the protein against substances that
were more disputed substrates of MRPL For example, previously published
reports have suggested MRP1 to be active against the MDR substrates
mitoxantrone (Morrow et al, 1998), vinblastine, and colchicine, while others
have found MRP1 to confer no increased resistance to these compounds (Cole et
al, 1994;Litman et al., 2000). Studies involving the anthracyclines doxorubicin
and daunorubicn have also suggested seemingly conflicting assessments of MRP 1
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transport. Although MRP1 expression has been associated with the
efflux of daunorubicin from cells, MRP 1-expression has not been associated with
the cellular efflux of doxorubicin, despite the observation that MRP1 expression
is sufficient to confer doxorubicin resistance (Cole et al, 1991). If MRP1 is not

conferring cellular resistance against doxorubicin by mediating its transport fro
the cell, then what other resistance mechanisms could it be promoting? We chose

to investigate these questions next using our fluorescence-based in vivo transpor
assays.

3.5 The Weak bases doxorubicin, daunorubicin, and mitoxantrone
We began first with the chemotherapeutic agents daunorubicin,
doxorubicin, and mitoxantrone. These weakly basic MDR substrates intercalate

between the bases of DNA, inhibit topoisomerase II activity, and disrupt cellular
replication (Vincent De Vita et al, 2001). All three compounds are naturally
fluorescent, and each has been suggested as an MRP1 substrate. In keeping with
previous reports, we found that MRP 1-EGFP expression substantially reduced the
intracellular accumulation of daunorubicin. HeLa cells transfected with MRP1EGFP and examined under confocal microscopy showed MRP 1-mediated
reduction in daunorubicin accumulation (Fig. 3-5, a-c), with MRP 1-expressing
cells (a) almost undetectable under daunorubicin fluorescence (b-c). However,
drug efflux assays of doxorubicin were more difficult to interpret. The MRP1ECFP expressing cells that were exposed to doxorubicin showed no significant
reduction in drug accumulation relative to non-expressing cells (Fig. 3-5, d-f).

The three cells in the center of the field in Fig. 3-5 (d), for example, were pos
for both EGFP and doxorubicin fluorescence (Fig. 3-5, e-f). It is interesting to
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note, though, that the nuclei of all three of these MRP 1-positive cells
showed almost no doxorubicin fluorescence. (Fig. 3-5, f, white arrow), while the
nuclei of non-expressing cells showed a predominantly nuclear accumulation of
the drug (Fig. 3-5, f, yellow arrow). Since MRP 1-expressing cells have been
reported to be resistant to the cytotoxic effects of doxorubicin, this decreased

sensitivity may be the result of altered patterns of drug distribution in these c
rather than the result of increased drug efflux. The nucleus is, after all, the
primary sub-cellular target of doxorubicin toxicity. This question of MRP 1mediated drug resistance will be discussed in greater detail in chapter 5.
Transiently transfected HeLa cells were next incubated in 2 uM
mitoxantrone. Cells with elevated MRP 1-EGFP levels (Fig 3-5, g, cell in the
upper center with an arrow), showed diminished levels of mitoxantrone
accumulation (Fig. 3-5, h). However, cells with lower levels of MRP1 (bottom

center of Fig. 3-5, g), had levels of mitoxantrone that were indistinguishable fr
non-expressing cells (Fig. 3-5, h). In the merged image (Fig. 3-5, i), we can
clearly distinguish a spectrum of drug accumulation that corresponds to the
degree of MRP 1-EGFP expressed in the cell. This pattern suggests that MRP1 is

indeed active against mitoxantrone, if not quite as active as against daunorubici
where EGFP fluorescence always correlated with drug exclusion. However, these

comparisons of MRP 1 activity are over-simplified, based on limited cell samples,

and highly dependent upon the viewer's visual interpretation of the data. In orde

to facilitate more rigorous comparisons of MRP 1 activity on different substrates
we decided to employ another fluorescence-based assay of drug transport,
fluorescence activated cell sorting or FACS. With FACS, fluorescence
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measurements are automated, and sample sizes are thereby increased
many orders of magnitude above those permitted by fluorescence microscopy.
When FACS-based analyses of MRP 1 activity were conducted on
daunorubicin, we found that the expression of MRP 1, represented by EGFP
fluorescence, was associated with decreased drug fluorescence (Fig. 3-6, a). The
range of MRP 1-EGFP fluorescence varied over 100-fold, and over this range of

expression, we saw drug reduction that, at its maximum, was slightly greater than
10 fold over background. Examinations of Pgp-mediated daunorubicin transport
revealed a nearly identical activity range (Fig. 3-6, b). We next examined MRP1mediated doxorubicin transport by FACS, and surprisingly enough, found that
MRP1 expression had little effect on the total intracellular accumulation of
doxorubicin (Fig. 3-6, c). This finding is in keeping with our studies of
doxorubicin transport under confocal microscopy (Fig. 3-5, d-f), and support our
preliminary hypothesis that MRP1 is altering patterns of intracellular drug
accumulation, rather than contributing to drug efflux from the cell. Moreover,

examinations of Pgp found a similar relationship: expression of the transporter d
not contribute to decreased drug accumulation (Fig. 3-6, d). These data, along
with the hypothesis that MDR transporters promote drug resistance by means
other than drug efflux, will be discussed in subsequent chapters.
Finally, flow cytometry revealed that MRP1 activity against mitoxantrone
(Fig. 3-6, e) was considerably diminished when compared to daunorubicin (Fig.
3-6, a). Cells expressing the highest level of MRP 1-EGFP showed considerably
less than a ten-fold reduction in drug accumulation (Fig. 3-6, e), an activity
comparable to Pgp-EGFP expressing cells (Fig. 3-6, f). This weak activity may
account for the differing assessments of mitoxantrone as a substrate of MRPL
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3.6 Microtubule-disrupting agents.
Thus far, we had seen that the expression of MRP 1 was capable of
decreasing the steady-state accumulation of fluorescent chemotherapeutic agents,
as assayed by their fluorescence. We next wanted to determine whether these
transport activities would also be able to reduce the cytotoxic effects of
chemotherapeutic agents and thereby contribute to drug resistance. For this line
of investigation, we chose to study another class of MDR substrates, microtubule
depolymerizing reagents like the vinca alkaloids and colchicine. If MRP 1-EGFP
expression alone mitigated the depolymerizing effects of these reagents, then
there would be a direct link between the expression of our fluorescent MRP1
construct and drug resistance. Moreover, we could also try to resolve for
ourselves the previous controversy in the field regarding the substrate status of
these drugs.
In order to proceed with these investigations, we needed a way of making
the cytotoxic effects of these reagents amenable to fluorescence-based assays of
MRP1 activity. In short, we needed a reliable method of visualizing microtubules
after drug incubation. At first, we attempted co-transfections of MRP1-EYFP and
tau-ECFP, the latter having been used as an indicator of microtubule structure in
cells previously (Schmoranzer and Simon, Mol. Biol. Cell, in press). However,
we needed long expression times (24-48 hours post transfection) to ensure
functional MRPL Unfortunately, these expression times resulted in the severe
over-expression of tau-CFP; the protein was no longer reliably associated with the
cytoskeleton and poorly represented the structure of microtubules (Fig. 3-7, a).
We next chose to fix cells and probe them with an anti-tubulin antibody, a method
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which yielded more reliable representations of the microtubule
cytoskeleton. This latter method was sensitive enough to detect elaborate
microtubule structures, including the microtubule organizing center or MTOC
(Fig. 3-7, b arrow), a sensitivity necessary for assaying degrees of microtubule
depolymerization in response to drug addition. In addition,
immunocytochemistry allowed us to augment our fluorescent assays of MRP 1
activity with another fluorescent protein: instead of co-transfecting with MRP1EYFP and tau-ECFP, we could now follow the fluorescence of MRP1-EYFP and
Pgp-ECFP and compare in this way the cyto-protective effects each protein
afforded.
For these assays, then, one set of HeLa cells was transfected with MRP1EYFP, another set was transfected with Pgp-ECFP, and these two sets were plated
on the same dish for visualization. Cells either expressed MRP1-EYFP, or PgpECFP, or they expressed no exogenous drug transporter and were therefore our
control population of cells. When cells transfected and plated in this way were
exposed to vincristine, and then examined for microtubule depolymerization, we
found that both MRP1 and Pgp provided substantial chemo-protection against the

cytotoxicity of vincristine (Fig. 3-8, a-e). The field of cells in Figs. 3a-e sho
one cell strongly expressing MRP1-EYFP (Fig. 3-8, a), two cells strongly
expressing Pgp-ECFP (Fig. 3-8, b), and a number of surrounding cells expressing
neither protein (Fig. 3-8, d). The microtubules of non-expressing cells were

severely disrupted by vincristine incubation, so much so that they had altered ce
morphology (Fig. 3-8, d). These cells were round and considerably smaller than
their MRP1-EYFP or Pgp-ECFP-tagged counterparts. However, the cell
expressing MRP1-EYFP and the two cells expressing Pgp-ECFP showed
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relatively little microtubule depolymerization; each cell had an intricate
microtubule network. The microtubule-organizing center was intact in Pgp-ECFP
expressing cells but not in the MRP1-EYFP expressing cells. Therefore, MRP1

provided some protection against the depolymerizing effects of vincristine, if no
as much as Pgp.
Next, we assayed the effect of MRP1-EYFP and Pgp-ECFP on colchicine
toxicity (Fig. 3-8, f-j). Cells incubated in 2 (iM colchicine were unable to
maintain microtubule integrity in the absence of either multidrug resistance

protein (Fig. 3-8, i). These cells were only diffusely stained with the anti-tubu
antibody, and they showed no discernable microtubule structure. The expression
of Pgp-ECFP, however, prevented this loss; the ECFP-tagged cell (Fig. 3-8, g)
had relatively undamaged microtubules, with the MTOC still intact (Fig. 3-8, h).
Similarly, the two MRP1-EYFP expressing cells (Fig. 3-8, f) had a complex
network of microtubules with the MTOC quite evident (Fig. 3-8, j).
Lastly, we examined the effect of expressing MRP1-EYFP on vinblastine
toxicity, once again in the presence of ECFP-tagged Pgp. The field of cells in
Figs. 3-8, k-n contained one MRP 1-expressing cell (Fig. 3-8, k), four Pgp-ECFP

expressing cells (Fig. 3-8,1) and a number of cells expressing neither protein (

3-8, n). Cells lacking both multidrug resistance proteins had clearly been affect
by vinblastine; they had no extant MTOC and considerably disrupted
microtubules (Fig. 3-8, n). All four cells expressing Pgp-ECFP showed relatively
undisrupted microtubule structures, with a MTOC somewhat visible in each cell
(Fig. 3-8, m). In contrast, the cell expressing MRP1-EYFP could not be

distinguished from the non-expressing cells (Fig. 3-8, o). As evident in the deta
of the anti-tubulin stained field (Fig. 3-8, o), the center cell with the least
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microtubule structure was the one transfected with MRPL The adjacent
cell had only a slightly disrupted MTOC and was also faintly labeled with ECFPtagged Pgp. The surrounding cells, which expressed neither MDR protein, had
microtubules that had been severely damaged by vinblastine. It seems therefore,
that MRP1, unlike Pgp, provides little to no protection against the effects of
vinblastine. This differential effect of MRP 1 expression on vincristine and
vinblastine had been previously reported (Cole et al, 1994).

3.7 Overview
In this chapter, we have seen that MRP 1-ECFP can be used as a reliable
indicator both of MRP 1 localization and activity. The fusion construct allowed us
to determine if the immediate introduction of MRP 1 altered the cellular response
to a chemotherapeutic challenge, and it did so in a way that correlated levels of
MRP 1-EGFP expression to the intracellular concentration of fluorescent
substrates. After brief incubations in compounds previously reported to be MRP1
substrates, HeLa cells expressing MRP 1-EGFP were examined for their ability
either to affect intracellular drug distribution or to mitigate cytotoxic damage. In
accordance with previous findings, MRP 1-EGFP expression resulted in
substantially diminished accumulation of TMRE and daunorubicin, and somewhat
reduced levels of mitoxantrone. However, MRP 1-EGFP had little effect on total
doxorubicin concentrations inside the cell. Surprisingly, though, cells expressing
the fusion construct did have significantly lowered doxorubicin fluorescence
inside the nucleus, a reduction which may be responsible for MRP 1-mediated
resistance against this chemotherapeutic. Whether this altered nuclear distribution
points to functional MRP1 away from the plasma membrane will be discussed in
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subsequent chapters. When MRP1 expression was assayed for its ability
to protect against the microtubule-depolymerizing effects of three
chemotherapeutic agents, the protein was found to substantially attenuate the
damage caused by colchicine, somewhat guard against vincristine-induced
microtubule disruption, and have no detectable effect against vinblastine.

cytosol
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Figure 3-1 Proposed topology of M R P 1 and M R P 1 - E G F P
a. A proposed topology of M R P 1 is presented, showing the five trans-membrane
(TM) domains thought to characterize its N-terminus, the remaining twelve T M
domains with their nucleotide binding domains (indicated with arrows), and the
three proposed glycosylation sites at Asn 19, Asn 23, and Asn 1006 (indicated by
branched symbols), b. A sketch of the protein n o w with E G F P (in green) added
to its C-terminus.
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Figure 3-2 E n d o g e n o u s expression of M R P 1 in H e L a cells.
a. H e L a cell lysates were probed after S D S page for the expression of endogenous
M R P 1 on an immunoblot with the M R P 1 antibody M R P r l . T w o bands were
detected near the 250 kDa protein marker, a result consistent with the reported 190
k D a m a s s for M R P 1 . The two fragments are thought to represent different
glycosylation states of the protein, b. H e L a cells were probed for the subcellular
distribution of endogenous M R P 1 with the M R P r l antibody. M R P 1 w a s found at the
plasma m e m b r a n e and in a sub-cellular compartment.

Figure 3-3 M R P 1 - E G F P transfected H e L a cells over-express full length M R P 1 - E G F P .
a-b. In lanes loaded with M R P 1 - E G F P transfected cell lysates, both an anti-MRP1 and an
anti-GFP antibody recognized a doublet of reduced electrophoretic mobility, a doublet that
would correspond to the addition of a 30 kDa E G F P to M R P 1 . N o proteolysis products
were recognized by either antibody, c-d. M R P 1 - E G F P transfected cells were probed with
an anti-MRP1 antibody and examined under confocal microscopy to determine the extent
of co-localization between the E G F P (c) and anti-MRP1 (d) fluorescent signals. E G F P
fluorescence w a s merged with the fluorescence derived from labeled M R P 1 (e) to
demonstrate the extent of the colocalization. f. The relative fluorescence intensities of
both labels were plotted in a line scan of the merged image. The scale bar for the
micrographs is 20 ^m.
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Figure 3-4 M R P 1 - E C F P is active against the M D R substrate T M R E .
a-c. M R P 1 - E C F P transfected HeLa cells were assayed for protein transport activity with
T M R E , a live-stain dye which is also a known M R P 1 substrate. The cell positive for
M R P 1 - E C F P expression (a) showed reduced T M R E accumulation (b-c) compared to its
n o n - M R P 1 - E C F P expressing counterparts (b-c). d-e. To determine whether the
reduction in T M R E accumulation w a s as a result of loss of cell viability or active, M R P 1 mediated transport, cells were treated with the M R P 1 inhibitor verapamil prior to the
T M R E assay. M R P 1 - E C F P expressing cells (d) n o w accumulated T M R E (e-f),
suggesting that M R P 1 - E C F P w a s capable of active transport.
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Figure 3-5 M R P 1 - E G F P has activity against weakly basic chemotherapeutic
agents. H e L a cells were transiently transfected with M R P 1 - E G F P and observed 48
hours after transfection for the accumulation of fluorescent chemotherapeutic drugs.
Cells incubated in 10 m M daunorubicin (a-c) showed nuclear and preinuclear
accumulation of the drug after 15 minutes (b); however, expression of M R P 1 - G F P (a)
substantially diminished the intracellular accumulation of daunorubicin, a pattern
m a d e evident in the merged image (c). W h e n transiently transfected HeLa cells were
incubated in doxorubicin (d-e), the expression of M R P 1 (d) w a s able to alter the
intracellular distribution of the drug so that it w a s no longer present in the nucleus (e).
T h e merged image (f) m a k e s this pattern clear. Finally, cells were incubated in 2 m M
mitoxantrone and observed for MRP1-mediated changes in drug accumulation (g-i).
M R P 1 expression (g) resulted in a slight decrease in mitoxantrone accumulation (h),
an observation m a d e clear in the merged image (i).

Figure 3-6 F A C S analysis of M R P 1 - E G F P activity.
a. The expression of M R P 1 - E G F P substantially diminished the intracellular accumulation of
daunorubicin, a reduction that w a s greater than 10 fold w h e n E G F P fluorescence w a s 100
fold over background, b. F A C S w a s also performed of daunorubicin accumulation in PgpG F P transfected cells for comparison, c. W h e n transiently transfected HeLa cells were
incubated in doxorubicin, no change in the total intracellular accumulation of the drug w a s
observed under F A C S for M R P 1 - G F P expressing cells over the entire range of E G F P
fluorescence, d. A F A C S analysis of P g p - E G F P expressing cells incubated in doxorubicin
w a s conducted for comparison, e. Cells were incubated in 2 n M mitoxantrone and
observed for MRP1-mediated changes in drug accumulation. M R P 1 expression only
resulted in a slight decrease in mitoxantrone accumulation in cells with the greatest E G F P
fluorescence, f. Pgp activity on mitoxantrone w a s used as a point of comparison.
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Figure 3-7 M e t h o d s of visualizing the microtubule cytoskeleton.
a. Hela cells were transfected with tau-ECFP and examined 24-48 h. later for
microtubule structure, b. H e L a cells were fixed and probed with a Cy3-labeled anti-B
tubulin antibody and then examined for microtubule structure.

Figure 3-8 Assaying M R P 1 transport of mictotubule depolymerizing agents.
HeLa cells were separately transfected with M R P 1 - E Y F P or Pgp-ECFP; cells were
plated together, and incubated in a microtubule-disrupting agent, and examined for the
extent of microtubule d a m a g e with a fluorescent anti-tubulin antibody, a-e. A n
incubation in 600 n M vincristine resulted in substantial microtubule disruption in cells
that did not express either M D R protein (c). Cells expressing M R P 1 - E Y F P (a) were
afforded s o m e chemo-protection against vincristine-mediated cytotoxicity (c, e), and
cells with P g p - E C F P (b) were relatively unaffected (c, d). f-j. Cells incubated in 2 m M
colchicine were examined for microtubule damage. M R P 1 - E Y F P expressing cells (f),
as well as P g p - E C F P expressing cells (g), maintained a complex microtubule structure
in the presence of colchicine (i), while non-expressing had almost completely
depolymerized microtubules (h,i,j). k-o. Incubating cells in 6 0 0 n M vinblastine
resulted in almost complete depolymerization of both M R P 1 - E Y F P expressing cells (k,
o) and non-expressing cells (m, n, o), whereas cells expressing P g p - E C F P (I) were
m u c h less affected by the drug (m-o).
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4 Chapter 4 Localization of MRP1
In the previous chapter, we demonstrated that the MRP 1-EGFP fusion

protein is functional, localizes to the plasma membrane, and has an activity prof
analogous to wild-type MRP1. We also saw that a fraction of the total MRP1

pool localized to a region within the cell and adjacent to the nucleus, and anoth
fraction to the plasma membrane. We next wanted to examine the sub-cellular
distribution of MRP 1, within two particular contexts. First, we wanted to
determine whether MRP 1-ECFP would undergo polarization-dependent sorting to
the plasma membrane in cells capable of polarization. Second, we wanted to
identify the sub-cellular organelles within which MRP1 might be found. Given
the fluorescent nature of the MRP1-ECFP construct, live cell-examinations of
MRP1 localization would be possible using fluorescence microscopy in

conjunction with live-cell fluorescent markers for sub-cellular organelles. Sever
such markers are commercially available and include reporters for the ER, the
Golgi, the recycling endosomes, and the lysosomes. Considering the peri-nuclear
localization of MRP 1, these particular markers would be helpful in determining
the organelle or organelles in which MRP1 might be found.

4.1 Expression in Polarized Cells
To determine whether MRP 1-ECFP would be expressed in a polarized
fashion in epithelial cells, polarized MDCK cells were transfected with MRP1ECFP and visualized 24 hours later, using deconvolution microscopy. This

technique collects light from multiple sections of a sample at specified distance
in the Z plane, in our case every 1.5 um, and using a nearest neighbor
deconvolution algorithm, reallocates out of plane fluorescence. Deconvolution
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microscopy thereby allows for a more direct sampling of cell sections,
and minimizes the contribution of fluorescent signals from other focal planes.
When MRP 1-ECFP transfected MDCK cells were examined in this fashion,
MRP 1-ECFP was found at the basal membrane (Fig. 4-1 a) and at the lateral

membrane (Fig. 4-1 b), but the protein was not present at the apical surface (Fig

4-1 c). This distribution is in contrast to the localization of MRP 1-ECFP in non

polarized cells. HeLa cells, for example, express the protein at the basal surface

(Fig. 4-1 d), the lateral surface (Fig. 4-1 e, arrow), as well as the apical surfa
(Fig. 4-1 f)- Baso-lateral localization for wild-type MRP1 has been previously
reported (Evers et al, 1996).

4.2 Perinuclear localization of MRP1-ECFP in multiple cell lines
In Hela cells, MRP 1-ECFP fluorescence was evident adjacent to the

nucleus. To ensure that this localization pattern was not specific to one cell ty
a number of other cell types were transfected with MRP 1-ECFP and examined

under wide-field epi-fluorescence microscopy for the sub-cellular distribution of
the protein. In the mouse embryonic stem cell line BDC1, for example,
fluorescence from MRP 1-ECFP was present in a region surrounding the nucleus
(Fig. 4-2 a, arrow), as well as at the plasma membrane. In this micrograph, the
rim-staining that generally characterizes plasma membrane-localized markers was
less visible. However, the apparent sub-cellular distribution of MRP 1-ECFP was

highly dependent upon the focal plane visualized for all the cells and cell types
used in this study. Depending upon the cell and the focal plane chosen, MRP1ECFP was more or less evident at the plasma membrane or the peri-nuclear region
for BDC1 cells (Fig. 4-2 a), for the immortalized mouse line NIH 3T3 (Fig. 4-2
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b), for the primary human fibroblast NHDF (Fig. 4-2 c), and for the
glutathione mutant mouse embryonic stem cell line GCS2-NAC (Fig. 4-2 d).
Hence, while peri-nuclear staining was clear in the micrograph of the NHDF cell

(Fig. 4-2 c), rim-staining was less evident. In the same fashion, the rim-stainin
of the NIH 3T3 cell was clear, while the peri-nuclear staining was not (Fig. 4-2

In some cases, the relative distribution of the organelles in a cell made a rim-s
and a peri-nuclear stain both evident (Fig. 4-2 d). Nevertheless, in all cells
examined for the sub-cellular distribution of MRP1-ECFP, the protein was found
both at the plasma membrane and in a peri-nuclear compartment.

4.3 Characterizing the sub-cellular distribution of MRP1
Since a significant fraction of the total MRP1 expressed in a cell localized
to an intracellular compartment, we next wanted to determine which organelle or
organelles were constituents of this compartment. To establish whether MRP1

resided in a particular organelle, we used fluorescent markers for organelles fou
in the peri-nuclear region of the cell, and we determined the degree of spatial

correlation between the fluorescent signal of the marker and the fluorescent sign
of MRPL We began our search with fluorescent reporters for the Golgi and the
recycling endosomes. For in vivo labeling of the Golgi, we used a fluorescentlytagged, truncated version of human Golgi resident protein beta 1,4-galactosyltransferase, a commercially available reporter (Clontech) shown to be a specific
marker for the trans Golgi compartment (Llopis et al, 1998). For the recycling

endosomes, we used cy-3 labeled transferrin, a protein which binds the transferri
receptor and is in this way interalized by the cell to label the recycling
endosomes (Lampson et al, 2001).

Chapter 4 M R P 1 Localization

45

HeLa cells were transfected with both MRP 1-ECFP and GolgiEYFP and then loaded with cy3-labeled transferrin. When cells were next
visualized using epi-fluorescent microscopy, we found that all three fluorescent
labels accumulated in a peri-nuclear region (Fig. 4-3, a-d). We could not easily
distinguish the degree to which MRP 1-ECFP signal derived from the Golgi or the
recycling endosomes, as the markers themselves overlapped. Moreover, because

the images represented light collected from the entire sample, we were not able t
distinguish localization patterns in the Z plane. In an attempt to spatially
segregate these markers, we treated cells with BFA, a reagent which induces
retrograde transport from the Golgi to the ER, and thus has the effect of
collapsing the Golgi apparatus back into the ER (Lippincott-Schwartz et al,
1990). If the MRP 1-ECFP signal emanated from the recycling endosomes, it
would not be affected by the addition of BFA. However, if peri-nuclear MRP1ECFP resided primarily in the Golgi, we would expect to see a more reticulate
distribution for the transporter upon BFA addition. When we added BFA to these
cells, we were not able to make a reliable assessment of the effect of BFA on
MRP1 localization, even after comparing cells in the same field before and after
the addition of the drug (Fig. 4-3, a-d vs. e-h). Cell movements between these
two visualization times made comparisons of cells pre-and-post BFA treatment

difficult, as we could not account for the changes in organellar distribution cau
by cell movement. Moreover, the addition of BFA did not completely collapse
the Golgi into the ER in every cell, and therefore the problem of overlapping
signals in the Z plane was not resolved.
In order to improve our resolution in the Z plane, and thereby distinguish
over-lapping markers in the peri-nuclear region, we decided to use deconvolution

Chapter 4 M R P 1 Localization

46

microscopy once again. HeLa cells transfected with MRP 1-ECFP were
incubated in cy3-transferrin to label the recycling endosomal compartment and
then sections of cells were examined for co-localization of the two markers.
Deconvolution microscopy enabled us to visualize individual MRP 1-ECFP
vesicles in the peri-nuclear region (Fig. 4-4 a), as well as individual vesicles
endosomal compartment (Fig. 4-4, b). The merge of these two fluorescent signals

(Fig. 4-4 c), as well as an enlarged image of the peri-nuclear region (Fig. 4-4 d
demonstrated that very little of the MRP 1-ECFP signal emanated from the
recycling endosomes. Vesicles contained either MRP 1-ECFP or cy3-transferrin.
Few, if any, contained both.
We decided next to determine whether MRP1 might reside in the Golgi,
by transfecting cells with MRP 1-ECFP and Golgi-EYFP, and once again
examining cells using deconvolution microscopy. Individual cell sections
revealed vesicles labeled with either MRP 1-ECFP (Fig. 4-5, a,d) or Golgi-EFYP

(Fig. 4-5, b,e), but rarely were there ever vesicles that expressed both fluoresc
markers together (Fig. 4-5, c, f). Similar results were obtained when cells were

transfected with MRP 1-ECFP and a fluorescent marker for the ER (Fig. 4-5, g-1).
Both MRP 1-ECFP and ER-EYFP were found in peri-nuclear vesicles, but there
was very little co-localization of these markers in these vesicles.
MRP 1-ECFP might also reside in the lysosomes. ABC proteins are
known to be expressed in the vacuole of non-mammalian systems (Li et al,
1996;Lu et al, 1997), and in mammals, proteins that are not part of the ABC
family do confer drug resistance from lysosomes (Cabrita et al, 1999).
Moreover, lysosomes may promote drug detoxification and in this way provide a
link between two distinct multidrug resistance pathways. We decided to test this
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possibility by chasing fluorescently-labeled dextrans into the lysosomes
of MRP 1-ECFP transfected cells. Fluorescent dextrans are routinely employed to
label the different stages of the endocytic pathway of living cells. When
incubated in fluorescent dextrans, cells will endocytose these particles, and
depending upon the length of the chase, the dextrans will reside in the early or
endosomes, or if given enough time, in the lysosomal compartment. The
lysosomes of MRP 1-ECFP transfected HeLa cells were labeled in this fashion,
and then examined for the degree to which the ECFP signal emanated from
regions of the cell that were positive for Texas-Red dextrans. Once again, MRP1ECFP fluorescence was evident at the plasma membrane and in a peri-nuclear
compartment (Fig. 4-6, a, d). Fluorescence from lysosomes (Fig. 4-6, b,e)

correlated spatially with that from MRP 1-ECFP (compare Fig. 4-6, d, with Fig. 5
6, e), and these two signals appeared to emanate from the same vesicles. To

verify these results with another marker for the lysosomes, we chose to co-expres
MRP1 with synaptotagmin VII, a lysosomal membrane protein that is also found
in some cell types at the plasma membrane. When Hela cells were co-transfected
with MRP1-EYFP and synaptotagmin VII-ECFP, we found that these cells had
vesicles positive for both fluorescent proteins (Fig. 4-7, vesicles of note are
circled for ease of identification).
These co-localization studies suggested that MRP 1-ECFP resides in the
lysosomes during some time in its trafficking history. As plasma membrane
proteins are routed to the lysosomal compartment for degradation, we became
concerned that the MRP1-ECFP present in this compartment may represent an
aberrant localization pattern, one introduced solely by the ECFP tag, perhaps as
result of a protein misfolding event that targeted MRP 1-ECFP for proteolysis.

Chapter 4 M R P 1 Localization

48

However, if the peri-nuclear fluorescence represented degraded protein,

it should have been detectable by Western blot, as intracellular MRP 1 constitute
a considerable fraction of the total protein expressed. Our previous
investigations of MRP 1-EGFP expression indicated that the large fraction of
MRP1-EGFP being expressed by the cell was not proteolyzed (Chapter 3). On

the other hand, it is possible that the lysosomal localization of the protein was

artifact of the ECFP tag, effecting the trafficking dynamics of the protein in wa
that misrepresented the localization of wild-type MRPL To determine if the

fluorescent tag was responsible for aberrant localization of MRP 1, synaptotagmin
VII was transfected into HeLa cells along with wild-type MRP1, and
immunocytochemistry was performed using the MRP 1 antibody MRPrl. We
found that wild-type MRP1 co-localized with synaptotagmin VII in a region
adjacent to the nucleus (Fig. 4-8, a-c). Under deconvolution microscopy, we

could distinguish vesicles which contained both MRP1 (Fig. 4-8, d, f circles) and
synaptotagmin VII (Fig. 4-8, e-f circles). As an added assurance, we wanted to
determine whether MRP1 would co-localize with another lysosomal marker. As
our fluorescent dextrans would not withstand the fixation process, we chose
another lysosomal resident protein for our studies, cathepsin D. In accordance
with our previous findings, wild-type MRP1 was found to co-localize with this
lysosomal marker as well (Fig. 4-9).
We next wanted to determine whether this lysosomal localization pattern
of MRP 1 would be exhibited by other ABC proteins, particularly those involved
in conferring drug resistance. We therefore transfected HeLa cells with
fluorescent conjugates of other MDR proteins, in particular, Pgp and BCRP, both

of which have been implicated in the acquisition of drug resistance in a clinical
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setting. As with MRP1, we used fluorescent conjugates of Pgp and

BCRP to examine the sub-cellular localization of these proteins. Both fluorescent
proteins have been examined in detail and have been found to be reliable markers
of wild-type Pgp and BCRP. Neither fluorescent conjugate is subject to extensive
proteolysis, as determined by Western Blot, and both proteins reduce the
intracellular accumulation of chemotherapeutic agents (Kartner et al, 1983).
When the lysosomes of Pgp-ECFP transfected HeLa cells were labeled with
fluorescent dextrans, we found that both fluorescent signals emanated from the

peri-nuclear region of the cell. Moreover, individual vesicles that contained bot
Pgp and the lysosomal marker were easily detected (Fig. 4-10, circles). In the
same fashion, we found BCRP-ECFP also to localize to lysosomal vesicles within
the perinuclear region of HeLa cells (Fig. 4-11).
However, when we examined an ABC protein not implicated in the
acquisition of multi-drug resistance, we found that the protein did not localize
the lysosomes. CFTR, like MRP1, Pgp, and BCRP, was studied as a protein
conjugate of ECFP, and its subcellular distribution was determined by employing

fluorescent dextrans chased into the lysosomes. The intracellular localization of
CFTR varied from cell to cell in each round of transfection, from a primarily
reticulate, intracellular distribution (Fig. 4-12, a) that most resembled the
distribution of an ER protein (Fig. 4-12, g), to a primarily plasma membranelocalized protein (Fig. 4-12, b). However, at no point did CFTR-ECFP co-

localize with lysosomal dextrans (Fig. 4-12, b, e), as evident in the merge of th

two fluorescent signals (Fig. 4-12, c, f). This data is suggestive of a functiona
relationship between drug resistance proteins and lysosomal targeting, a pattern
that we will discuss further in the next chapter.
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4.4 Quantifying co-localization
Thus far, determinations of co-localization had been performed entirely by
visual inspection. We now wanted to quantify the degree to which MRP1, or any
other fluorescent ABC protein, could be said to reside in one organelle, or another,
and thereby remove the arbitrary nature of visual assessments. Moreover,
quantification of visual data would enable us to compare the results of different
experiments and enable us to assess relative degrees of correlation between
different fluorescent markers. In order to do this, we used a correlation algorithm
available to us from MetaMorph software. For a given micrograph, this algorithm
determines the degree to which distinct fluorophores vary their intensities through a
two-dimensional space in a coordinated fashion, and represents this information in a
"correlation coefficient." Correlation coefficients are expressed on a scale of-1 to
1, with -1 representing no correlation whatsoever, and 1 representing identity. To
better understand the nature of this quantification, we wanted to test the scaling
system by acquiring correlation coefficients for either end of the spectrum: for
proteins that should co-localize entirely and therefore represent identity, and for
proteins that should share very little in their sub-cellular distribution.
To test the former, we began by transfecting cells with two versions of the
same protein, MRP1-EYFP and MRP 1-ECFP. Differing only in their fluorescent
tags, these proteins should share similar localization patterns and set the upper limit
of co-localization. When HeLa cells were co-transfected with MRP1-EYFP and
MRP 1-ECFP, we found that the two proteins did share very similar distributions;
again both were targeted to the plasma membrane and a peri-nuclear region (Fig. 413 a-c). Closer inspection of the peri-nuclear region revealed individual vesicles
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that shared the two fluorophores (Fig. 4-13, d, e; for example, circle 1).
However, there were also a number of vesicles that contained predominantly one
fluorophore over another (Fig. 4-13, d,e; for example, circle 2). Indeed, there were
surprising differences in the vesicular distribution of these two proteins, differences
which would made a correlation co-efficient of 1 less likely (Fig. 4-13, d,e, other
circles). When these images were analyzed for correlation coefficients, we found
an average assignment of 0.7677 for MRP1-EYFP and MRP 1-ECFP.
To find the lower limit of co-localization, we chose to examine Golgi-EYFP
transfected cells whose recycling endosomes were labeled with cy-3 transferrin
(Fig. 4-13, f-h). The correlation coefficient for this pair was 0.2699, suggesting that
even distinct organelles are characterized by overlapping pixels. This correlation
co-efficient may represent patterns of vesicular exchange between the organelles, or
it may be an artifact of pixel density and distribution in the confined space of a cell.
Nevertheless, we allowed this correlation co-efficient, along with that found for the
doubly transfected MRP1 expressing cells, to define the limits of our quantification.
With these limits in mind, we then generated correlation co-efficients for the
micrographs analyzed thus far for co-localization, and plotted them on a line graph
(Fig. 4-14, a-c). These numerical assessments of co-localization supported our
previous understanding of MRP 1 localization. MRP1, like MRP 1-ECFP, localizes
primarily to the lysosomal compartment 24-48 hours after transfection (Fig. 4-14
a,b). Very little of the protein is found in the ER, the recycling endosomes, or the
Golgi (Fig. 4-14, a). Analysis of the localization of Pgp-ECFP and BCRP-ECFP
suggest a similar pattern; both proteins can be found primarily in the lysosomal
compartment 48 hours after transfection, while CFTR-ECFP, a non-MDR ABC
protein, is not to be found there (Fig. 4-14, c).
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The demonstration of a lysosomal distribution for MRP1, Pgp, and
BCRP, does not preclude sub-cellular localization elsewhere. Indeed, this

intracellular distribution may be a factor of cell cycle or trafficking history, a

these proteins may present themselves in other locations under different condition
or at different times. MRP2, for example, has been found in a novel subcellular
organelle in nonpolarized hepatic cells (Tuma et al, 2002). However, it would not
be unprecedented to propose that MRP1, BCRP, and Pgp all reside in the
lysosomes. ABC proteins are known to be expressed in the vacuole of nonmammalian systems (Li et al, 1996;Lu et al, 1997), and in mammals, proteins that
are not part of the ABC family do confer drug resistance from lysosomes (Cabrita
al, 1999). Moreover, lysosomes may promote the detoxification of the drug and in
this way provide a link between two distinct multidrug resistance pathways.

Whether this sub-cellular localization pattern of these MDR transporters is a res

of over-expression is not known. In so far as multidrug resistant cancer cells are
known to over-express ABC transporters like MRP1, the over-expression system
used in this study models itself after a patho-physiological state. However,

predominantly intracellular localization patterns for MRP1 have been reported for
many normal tissues (Flens et al, 1996;Wioland et al, 2000). Moreover, we found

that cells expressing even low levels of MRP1-CFP were characterized by primarily

intracellular versions of the protein, suggesting that vesicular MRP1 may not be t
result of over-expression.
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Figure 4-1 M R P 1 - E C F P is sorted to the baso-lateral m e m b r a n e .
a-c. M R P 1 - E C F P w a s transfected into M D C K epithelial cells after
polarization and examined 24-48 hours later. M R P 1 - E C F P w a s observed
at the basal surface and the lateral surface, but not the apical surface in
these cells, d-f. Non-polarized cells transfected with M R P 1 - E C F P
expressed the protein at the plasma membrane. Arrows indicate lateral
surface.
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Figure 4-2 M R P 1 - E C F P localization in four cell types. M R P 1 - E C F P localizes
to the plasma m e m b r a n e and, to varying degrees, a peri-nuclear region, as seen
in four different cell types. Cell types are as follows: a. a m o u s e embryonic cell
line; b. an immortalized m o u s e cell line; c. a primary, h u m a n fibroblast line; and d.
a m o u s e embryonic cell line incapable of glutathione production. Arrows indicate
the peri-nuclear region.

Figure 4-3 Localizing organelles with epi-fluorescent microscopy a-d. Hela
cells transfected with M R P 1 - E C F P and Golgi-EYFP were labeled with Cy3-Tfn to
visualize recycling endosomes. Cells showed a perinuclear staining for all three
fluorescent signals, making sub-cellular determinations of M R P 1 - E C F P localization
difficult, e-h. The addition of B F A did not clarify M R P 1 - E C F P distribution patterns,
as cell movement m a d e comparisons between pre-and-post B F A addition difficult.
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Figure 4-4 M R P 1 - E C F P d o e s not localize to the recycling e n d o s o m e s .
a-c. M R P 1 - E C F P transfected cells were loaded with cy3-transferrin and examined with
a deconvolution fluorescent microscope to determine the degree to which the M R P 1 E C F P signal (a) co-localized with the recycling endosomes (b). O n e section of the cell
is presented, d-e. A n enlarged image of the cell depicted in (a-c) m a k e s evident the
degree to which M R P 1 - E C F P does not co-localize with the recycling endosomal
compartment. T h e vesicles containing each fluorescent signal are distinct.
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Figure 4-5 M R P 1 - E C F P d o e s not localize to the Gogli or the E R
a-c. Hela cells were transfected with both M R P 1 - E C F P (a) and Golgi-EYFP (b),
and examined with a deconvolution fluorescent microscope to determine the
extent of the colocaliztation. d-e. A n enlarged image of the cell above in which
vesicles containing one or the other of the two fluorescent markers are clear, g-l.
Hela cells were transfected with M R P 1 - E C F P (g, j) and E R - E Y F P (h, k) to
determine the extent of the co-localization. F e w vesicles, if any, were
simultaneously labeled with two fluorescent signals.
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Figure 4-6 M R P 1 - E C F P co-localizes with a lysosomal marker
a-c. M R P 1 - E C F P transfected Hela cells were incubated with fluorescent
dextrans that were chased into the lysosomes. The M R P 1 - E C F P signal (a, d)
correlated with that of the lysosomal marker (b, e), as seen in the merged image
(c, f). Three second time delays occurred between image acquisitions, during
which time, vesicular m o v e m e n t precluded absolute spatial resolution of the two
fluorophores.

Figure 4-7 M R P 1 - E Y F P co-localizes with synaptotagmin VII
a-c. Hela cells were transfected with M R P 1 - E Y F P (a) and synaptotagmin VII (b), a
lysosomal m e m b r a n e marker, and then were imaged using deconvolution microscopy.
A section of a cell is presented in which s o m e of the vesicles that clearly express both
proteins are circled.
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Figure 4-8 Wild type M R P 1 co-localizes with synaptotagmin VII
a-c. H e L a cells were transfected with M R P 1 and synaptotagmin VII (a) and then probed
with the anti-MRP1 antibody M R P r l for the presence of wild type M R P 1 (b) in
lysosomes. d-f. A n enlarged section of a cell co-transfected with wild-type M R P 1 and
synaptotagmin VII. Circles indicate vesicles that are positive for both proteins.
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Figure 4-9 Wild-type M R P 1 co-localizes with the lysosomal marker
cathepsin D
a-c. M R P 1 transfected H e L a cells were fixed and probed for wild-type
M R P 1 (a) as well as the lysosomal resident protein cathepsin D (b).
O n c e cell section is represented, d-f. A n enlarged image of another
section of the s a m e cell presented in a-c.
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Figure 4-10 P g p - E C F P can also be found in vesicles positive for a
lysosomal marker
a-c. A H e L a cell w a s transfected with P g p - E C F P (a) and then labeled with
fluorescent dextrans chased into the lysosomes (b). Circles call attention to
vesicles containing both fluorescent signals.
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Figure 4-11 B C R P - E C F P is found in lysosomes
a-c B C R P - E C F P transfected cells were loaded with fluorescent dextrans to label the
lysosomes. B C R P - E C F P (a) w a s found in vesicles in the peri-nuclear region of cells,
and these vesicles were positive for fluorescent dextrans (b), as seen in the merge (c).
d-f. A n enlarged region of a B C F P - E C F P transfected cell in which vesicles positive for
B C R P (d) and fluorescent dextrans (e) are apparent (circles, f)
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Figure 4-12 C F T R - E C F P is not found in lysosomes.
a-f. T h e lysosomes of H e L a cells transfected with C F T R - E C F P (a, d) were labeled with
fluorescent dextrans to determine whether C F T R could be found in the lysosomes. g.
A H e L a cell transfected with E R - E Y F P is shown as a point of comparison.

M R P 1 - E Y F P

M R P 1 - E C F P
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Figure 4-13 Determining the limits of co-localization.
a-c. H e L a cells were transfected with M R P 1 - E Y F P and M R P 1 - E C F P to determine
the extent of the co-localization of the two markers, d-e. A n enlarged image of the
cell presented in a-e, in which vesicles containing the two fluorophores are visible.
Circles indicate variability in co-localization in a positive control, f-h. The Golgi
apparatus and the recycling endosomal compartment were labeled in HeLa cells to
determine the extent of their co-localization.
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Figure 4-14 Correlation Coefficients permit quantification of protein colocalization studies, a. Correlation coefficients for M R P 1 - E C F P and various
subcellular markers are plotted. Correlation coefficients for wild-type M R P 1 and
the lysosomal compartment are plotted, c. Correlation coefficients for other
A B C proteins and the lysosomal compartment are plotted.
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5 Chapter 5 Subcellular activity of MRP1

5.1 Drug sequestration
In the last chapter, we determined that MRP1 localizes both to the plasma
membrane and to an intracellular compartment that is positive for at least three

different lysosomal markers. We found that this distribution pattern characterize
the expression of MRP 1-ECFP, as well as the expression of wild-type MRPL

We also discovered that this subcellular localization pattern was shared by other
MDR-conferring proteins, transporters like P-glycoprotein and BCRP, but not by
other ABC proteins, like CFTR. We now wanted to determine whether this
intracellular distribution was of any physiological relevance to the cell. In
particular, we wondered whether these MDR proteins could be active in these
compartments, and whether this activity could contribute to drug resistance.
There is some precedence for suggesting that these proteins might be
functional within sub-cellular compartments. Non-mammalian members of the
ABC family, for example, are known to be active in intracellular compartments.
The yeast cadmium factor 1 (YCF1) and plant homologues of the human MRP1,
Arabidopsis thaliana MRP1 and MRP2, are all thought to transport substances
from the vacuolar membrane into the vacuole (Li et al, 1996;Lu et al, 1997;Lu et
al, 1998). As the storage compartment for toxins of varied sources, the vacuole

serves in a drug resistance capacity, sequestering everything from herbicides and
anti-microbial agents to oxidizing metabolites from the rest of the cell. In a
similar fashion, the lysosomal compartment, where we have found human MRP1

to reside, has been implicated in an analogous role: providing drug resistance by
sequestering toxins away from the rest of the cell (Hurwitz et al, 1997). The
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MCF7-Adr cell line, for example, is a multidrug resistant line whose
drug resistance is in main part due to the sequestration of drug away from the
nucleus in lysosomes, as well as other intracellular organelles (Altan et al, 1998)
(Fig. 5-1, a). In contrast, the parental line, MCF7, is sensitive to chemotherpeutic
agents like doxorubicin which accumulates in the nucleus, the site of doxorubicin
toxicity (Fig. 5-1, b).
Drug sequestration is a well-characterized mechanism of conferring drug
resistance, and it is thought to be mediated by altered intracellular pH. Drug
resistant cells frequently have intracellular compartments that are acidified and
therefore more likely to accumulate weakly basic drugs like doxorubicin.
Disrupting cellular acidification with the addition of concanamycin A, for
example, results in the redistribution of chemotherapeutics into the nucleus of
some drug resistant cell lines like MCF7-Adr (Fig. 5-1, c) (Altan et al, 1998).
However, it is possible that other drug sequestration mechanisms are at work here.
MCF7-Adr cells are known to express both MRP1 (see the following chapter) and
Pgp. Inhibiting the activity of these two proteins with verapamil redistributes
doxorubicin away from sub-cellular compartments and into the nucleus (Fig. 5-1,
d), suggesting a role for one or both of these proteins in altering drug distribution.
Moreover, doxorubicin in these cells is sequestered in the lysosomes, and may
suggest that lysosomally-localized MRP1 and Pgp are both active and contribute
to drug sequestration (Fig. 5-l,e). Finally, the expression of MRP 1 in the MCF7
sensitive line is sufficient to redistribute the drug away from the nucleus into subcellular organelles (Fig. 5-2, a-f), in pH independent manner (Fig. 5-2, d-f), much
like MCF7-Adr cells.
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For all of these reasons, we wanted to determine whether MRP1
retained transport activity within sub-cellular organelles. In order to investigate
this question, we asked the following questions: one, are drug substrates found to
co-localize with MRP 1-containing organelles; two, is this co-localization
reversible upon the inhibition of MRP 1 activity; three, is drug accumulation into
MRP1 organelles affected by alterations in organellar pH; and four, if the activity
of cell surface MRP1 is blocked, will drug accumulation in MRP 1-positive
organelles still occur? In this fashion, we would test if patterns of intracellular
drug accumulation correlated with intracellular MRP1 activity, and not with other
cellular phenomena frequently associated with drug resistance.

5.2 Doxorubicin localizes to MRP1-ECFP containing vesicles
We first compared the drug accumulation patterns of cells transfected with
MRP 1-ECFP to those expressing only endogenous MRP1 (Fig. 5-3). We found
that HeLa cells with only endogenous MRP1 accumulated doxorubicin in the
nucleus, and to a lesser extent, in vesicle-like structures around the nucleus (Fig.
5-3, a-c). For the most part, these structures did not co-localize with a marker for
the lysosomes (Fig. 5-3, d-f); however, this conclusion is suggested only by epifluorescence microscopy, and extensive studies have not been conducted
regarding this question using either confocal or deconvolution microscopy.
However, the expression of MRP 1-ECFP in HeLa cells resulted in a dramatic
redistribution of doxorubicin fluorescence, with almost no visible fluorescence
emanating from the nucleus, and an enriched accumulation of the drug in a perinuclear region (Fig. 5-3, h) that co-localizes with peri-nuclear MRP1 (Fig. 5-3, g,
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To determine whether doxorubicin in this peri-nuclear
compartment was indeed accumulating in MRP 1-containing organelles, we
examined the localization of both using deconvolution microscopy. We found
that the peri-nuclear region positive for both doxorubicin and MRP 1-ECFP (Fig.
5-4, a-c) was composed of what looked liked individual vesicles containing both

fluorophores (Fig. 5-4, d-f). In this case, the merge of the two images (Fig. 5-4
did not always result in yellow where the vesicles co-localized. Because these
images represent living cells with rapidly moving vesicles, one second time
delays between the acquisition of the images sometimes precluded absolute
spatial co-localization. Additionally, the relative intensities of the two

fluorophores are not matched, and vesicles labeled with more of one reporter than
another do not appear yellow.
Infrequently, MRP 1-ECFP was localized anomalously in HeLa cells; that
is, it was found in regions other than the plasma membrane and the perinuclear
region. This observation was not unexpected, as Hela cells are not clonal, but a

genotypically heterogeneous, transformed cell line. In an extremely rare instance
for example, MRP 1-ECFP accumulated in what appeared to be large aggregates
within the endo-membrane system (Fig. 5-4, g). Surprisingly, in this same multinucleated MRP 1-ECFP expressing cell, doxorubicin was also found distributed
throughout the endo-membrane system (Fig. 5-4, h) in a pattern very similar to
the distribution of MRP 1-ECFP (Fig. 5-4, i). Doxorubicin only assumed this
dispersed sub-cellular distribution when MRP 1-ECFP was likewise dispersed, and
never in a cell that was not transfected with an MDR protein. Despite this

anomalous localization pattern for MRP1, the protein was still active in the cell

and the expression of MRP 1-ECFP still resulted in the exclusion of the drug fro
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the nucleus (Fig. 5-4, h). The observation that the intracellular
distribution of doxorubicin varies with the intracellular distribution of MRP1ECFP is suggestive that the protein has sub-cellular activity.
Moreover, in instances when the MRP 1-ECFP plasmid was poorly
expressed in HeLa cells, the protein was found only in intracellular
compartments, and not at the plasma membrane at all (Fig. 5-4, j). This result
suggests that the intracellular localization of the protein is not an artifact of an
over-expression system. However, despite weak expression of this protein, cells
like this one still accumulated the drug in MRP 1-ECFP expressing vesicles, even
if expression of the protein was not sufficient to exclude the drug from the
nucleus (Fig. 5-4, k-1).
Therefore, in addition to the plasma membrane, MRP 1-ECFP localized to
intracellular compartments that were peripheral to the nucleus. Within these
vesicles, MRP 1-ECFP fluorescence was coincident with doxorubicin
fluorescence, a finding which would be consistent with MRP 1-mediated
sequestration of the drug away from the nucleus. In rare instances, when a cell
exhibited an altered pattern of intracellular MRP1 distribution, doxorubicin also
assumed this altered pattern, arguing strongly that intracellular MRP 1 actively
transports doxorubicin.

5.3 Doxorubicin sequestration in MRPl-vesicles is dependent on MRP1
activity
We next wanted to determine if doxorubicin accumulation in MRP1containing vesicles was dependent upon MRP1 activity, or simply a result of
altered pH in MRPl-vesicles. If intracellular MRP1 is to be found predominantly
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in the lysosomal compartment, then the lysosomal accumulation of a
weakly basic chemotherapeutic like doxorubicin could simply be a function of
acidification in these compartments. We therefore assayed the effect of
concanamycin A on the sub-cellular distribution of doxorubicin in MRP 1-ECFP
expressing cells. Concanamycin A inhibits organellar acidification, as assayed by
the pH sensitive dye acridine orange, which fluoresces in the red in a low pH
environment (Fig. 5-5, a-b). In the absence of concanamycin A, acridine orange
staining in the organelles peripheral to the nucleus is red (Fig. 5-5, a); after the
addition of concanamycin A, red fluorescence is significantly reduced (Fig. 5-5,
b), suggesting the reagent is inhibiting organellar acidification in these cells. We
then added doxorubicin to concanamycin A-treated cells, and found that
doxorubicin-sequestration was unaffected (Fig. 5-5, c-e). Thus, in HeLa cells
over-expressing MRP1, alterations in cellular pH were unable to alter doxorubicin
distribution, a finding in contrast with MCF7-Adr cells (Fig. 5-1, c) which have
no doubt developed many different mechanisms of drug resistance during their
protracted drug selection.
To determine whether the co-localization of doxorubicin and MRP1 in
intracellular compartments was mediated by MRP1 activity, we inhibited MRP1
activity with verapamil, and then observed the distribution of doxorubicin. As
expected, verapamil-treated cells accumulated doxorubicin primarily in the
nucleus (Fig. 5-5, f-h), regardless of the degree to which they expressed MRP1ECFP. More interesting however was the almost total absence of peri-nuclear
doxorubicin in these cells (Fig. 5-5, g). As a result of inhibiting MRP1 activity,
doxorubicin accumulation in the nuclear periphery was also blocked, and MRP1ECFP cells treated with verapamil had no more vesicular doxorubicin
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accumulation than cells not transfected with MRP 1-ECFP (Fig. 5-5, i).
These results suggest that the expression of MRP 1-ECFP alone is responsible for
the peri-nuclear accumulation of doxorubicin.
We had now established that intracellular MRP 1-ECFP co-localizes with
doxorubicin and that this co-localization is mediated by MRP1 activity. We next
wanted to determine whether this intracellular MRP1 activity alone was sufficient
to promote the classic doxorubicin-resistant phenotype: exclusion of the drug
from the nucleus. We have seen that there are two pools of MRP 1, one at the cell
surface, and one at the periphery of the nucleus. It is possible that the nuclear
drug exclusion found in MRP 1-ECFP expressing cells is a result of MRP 1 activity
at the surface of the cell. Although FACS analysis did suggest that MRP1
expression only minimally, if at all, reduced the total doxorubicin uptake in HeLa
cells (see chapter 4, Fig. 4-6, c), these data represent relationships on a log scale;
less dramatic, but perhaps still physiologically relevant, decreases might be
missed. Thus, it was still possible that MRP1 at the plasma membrane was
reducing intracellular drug accumulation and this reduction alone was responsible
for nuclear drug exclusion. Intracellular MRP 1 activity may have been unrelated
to the decreased nuclear accumulation of the drug in MRP 1-expressing cells.
To investigate this possibility, we needed a way of inhibiting MRP1
activity only at the cell surface. With MRP1 blocked at the cell surface, we could
then assay whether intracellular MRP1 could still sequester the drug in MRP1containing vesicles, and whether this activity was sufficient to decrease drug
accumulation in the nucleus. For this purpose, we employed the help of two
cysteine-based cross linking reagents, BM[PEO]4 and BMH. The first is a cellimpermeable reagent which, if it blocked MRP1 activity, would do so only at the
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cell surface, and in this way we would be able to isolate the activity of
intracellular MRPl. The second would block both pools of MRP 1, if it inhibited

MRP 1 at all. However, before using either cross-linking reagent, we needed to be
sure that these reagents would block MRPl activity without impairing cell

viability. If cells were viable after the administration of the cross-linkers, an
MRPl activity were inhibited by their administration, then these reagents would
provide us a way of investigating the role of intracellular MRPl activity in
nuclear drug exclusion.
MRPl sensitivity to these reagents was gauged with the compound
tetramethyl rhodamine ester (TMRE). TMRE is a fluorescent MDR substrate that
does not accumulate inside MRPl-expressing cells, but instead, is effluxed from
the cell in an MRPl-dependent manner. TMRE is also a live stain dye; drug entry
is dependent on the maintenance of plasma membrane potential, and upon cell
entry, TMRE accumulates in the mitochondria (Farkas et al, 1989). With TMRE,

we could assay the effects of the cross-linking reagents on both cell viability a
MRPl activity at the same time. If after addition of these reagents, TMRE
entered all cells regardless of the degree to which they expressed MRPl, the

cross-linking reagents could next be used to assay intracellular MRPl activity on
doxorubicin.
When cells were exposed to TMRE (Fig. 5-6, a-c), the MRPl-expressing

cell (Fig. 5-6, a) accumulated little to none of the drug, while cells that did n
express detectable levels of the MRPl-ECFP took up the drug in the mitochondria
(Fig. 5-6, b-c). Treatment with the MRPl inhibitor verapamil rendered MRP1ECFP cells incapable of effluxing TMRE (Fig. 5-6, d-e), and all cells
accumulated the dye in the mitochondria comparably (Fig. 5-6, f). These results
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suggest that TMRE exclusion from the cell is mediated by MRPl.
Crosslinking with the cell impermeable reagent BM[PEO]4 affected MRPl-ECFP
expressing cells much as verapamil did; all cells accumulated TMRE to the same
extent, regardless of the degree to which they expressed MRPl (Fig. 5-6, g-i).
Likewise, when cells were cross-linked with the cell permeable reagent BMH,
MRPl-dependent efflux of TMRE was also inhibited (Fig. 5-6, j-l). The fact that
cells accumulated TMRE after the addition of either BMH or BM[PEO]4 suggests
that cross-linking did not compromise cell viability. The fact that addition of
these reagents inhibited MRPl-dependent TMRE transport suggests that crosslinking is sufficient to block MRPl activity. Moreover, if BM[PEO]4 is only
reacting with MRPl-ECFP at the cell surface, then these results indicate that
MRPl activity at the plasma membrane is responsible for the absence of TMRE
in cells.
In order to determine whether BM[PEO]4 was inhibiting MRPl
selectively at the plasma membrane, we next tested the effect of BM[PEO]4
addition on sub-cellular pools of MRPl-ECFP. Because doxorubicin

accumulates in MRPl- containing vesicles (Fig. 5-4, d-f), we tested the effect of

BM[PEO]4 treatment on the intracellular distribution of the drug. Used in concert
with BMH treatment, this experiment would test if BM[PEO]4 was inhibiting
primarily plasma membrane MRPl and what role, if any, intracellular MRPl
activity played in doxorubicin sequestration.
When BM[PEO]4 treated cells were exposed to doxorubicin (Fig. 5-7, ac), doxorubicin did not accumulate in the nucleus of a cell expressing MRP1ECFP even though MRPl activity against TMRE is blocked with this treatment.
Indeed, the MRPl-ECFP expressing cell (Fig. 5-7, a) continued to be
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characterized by perinuclear doxorubicin staining (Fig. 5-7, b) which

corresponds to the localization of intracellular MRPl (Fig. 5-7, a, c). In contra
when cells were exposed to the cell permeable cross-linker BMH, prior to

doxorubicin incubation (Fig. 5-6, d-f), all cells accumulated the drug within the
nucleus, much as they did when treated with verapamil. These results reveal that
BM[PEO]4 affected the activity of MRPl-ECFP primarily at the plasma
membrane, whereas BMH inhibited MRPl throughout the cell.
From these experiments, we can safely make the following observations.
First, BMH and BM[PEO]4 do not affect cell viability. Second, MRPl activity at
the surface of cells is responsible for the absence of TMRE accumulation in
MRPl-expressing cells, and the addition of the cell impermeable BM[PEO]4
blocks cell surface activity. Third, loss of cell surface MRPl activity upon
BM[PEO]4 addition only marginally effects nuclear doxorubicin accumulation in
MRP 1-expressing cells. Finally, only the additional loss of intracellular MRPl
activity is sufficient to redistribute doxorubicin to the nucleus. These results
strongly suggest that intracellular MRPl is responsible for intracellular
doxorubicin sequestration, a drug resistance phenotype.

5.4 BM[PEO]4 and BMH cross-link MRP1-ECFP
We next tested whether BMH and BM[PEO]4 are affecting MRPl activity
by directly cross-linking MRPl-ECFP; if so, the electrophoretic mobility of
MRPl should be altered by treatment with either reagent. When cell lysates of
MRPl-ECFP transfected cells were immunoblotted with the anti-MRP 1 antibody
MRPrl, the antibody recognized a doublet that migrated near a 250kDa protein
standard. However, when cell lysates of BM[PEO]4 treated cells were similarly
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probed, the antibody recognized a much more slowly migrating species
of the protein, suggesting that the reagent was cross-linking MRPl directly.
Likewise, when cell lysates of BMH treated cells were probed with the antiMRP 1 antibody, we see similar changes in the electrophoretic mobility of the

protein (Fig. 5-8, a). We have reason therefore to believe that cross-linking wit
either reagent inhibits MRPl as a result of direct protein modification.

5.5 BM[PEO]4 and BMH do not increase cell permeability to MRPl
substrates
Even if MRPl is being directly modified by these cross-linking reagents, it
is possible that treatment with BM[PEO]4 or BMH is not inhibiting MRPl, but
simply increasing cell permeability to TMRE. In order to investigate this
possibility, we determined the average TMRE accumulation in a population of
cells as a function of MRPl expression, and we determined whether this average
was altered by the addition of cross-linker (Figure 5-8, b). When we calculated
these averages, we found that neither BM[PEO]4 nor BMH had any effect on
TMRE accumulation in cells that expressed MRPl-ECFP at background levels.
We did find, however, that BM[PEO]4 was able to block MRPl activity on
TMRE almost entirely; all BM[PEO]4 treated cells accumulated TMRE
equivalently, even at high levels of MRPl expression. On the other hand, BMH
inhibition of MRPl activity was not complete at the concentration of BMH used
(Figure 5-8, b). However, since BMH enters cells and is free to interact with

many intracellular cysteines, it might be more difficult to inhibit MRPl activity

with BMH at a concentration that would not at the same time be lethal to the cell
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We next performed statistical analyses on BM[PEO]4-treated
cells that were exposed to doxorubicin. We found that the concentration of the
cell impermeable crosslinker that was able to block MRPl activity on TMRE had
a marginal effect on doxorubicin distribution. After treatment with BM[PEO]4,
MRPl-ECFP expressing cells still showed a statistically significant reduction in
nuclear drug accumulation, if not as much as untreated MRPl-ECFP cells (Fig. 5-

8, c). In contrast, when cells were treated with BMH, the nuclear fluorescence of
the drug was not reduced by the expression of MRPl-ECFP, as it was in control

cells (Fig. 5-8, c). Thus, at a concentration of BMH that was only partially able
block MRPl-mediated TMRE efflux, MRPl activity against doxorubicin was
inhibited. Since BM[PEO]4 treatment completely inhibited MRPl-ECFP activity
at the plasma membrane, as assayed by loss of TMRE efflux, but had little effect

on the sub-cellular localization of doxorubicin, we have reason to believe that t
intracellular pool of MRPl-ECFP unaffected by BM[PEO]4 treatment is
responsible for doxorubicin sequestration.

5.6 Expression of Pgp and BCRP also results in analogous doxorubicin
sequestration
If the intracellular activity of MRPl is capable of mediating drug
sequestration and thus presenting a drug-resistance phenotype, we wondered
whether other MDR proteins would also be able to function in this way. We have
already seen that BCRP and Pgp, for example, are expressed in compartments

peripheral to the nucleus, in regions that are positive for lysosomal markers (Fi

5-9, a-c, and Fig. 5-9, g-i). Therefore, we decided to test the effect of express
these proteins on doxorubicin accumulation. When BCRP-ECFP-transfected cells
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were incubated in the drug, we found once again that doxorubicin
accumulated in the nucleus of non-expressing HeLa cells. However, the
expression of BCRP-ECFP (Fig. 5-9, d) redistributed the drug away from the
nucleus into BCRP-positive vesicles (Fig. 5-9, e-f). In a similar fashion, Pgp-

expressing vesicles that were positive for lysosomal markers (Fig. 5-9, g-i) also

accumulated doxorubicin (Fig. 5-9, j-l), and this accumulation correlated with lo
of nuclear doxorubicin fluorescence. For these reasons, we suspect that
intracellular Pgp and BCRP also function to sequester doxorubicin from the
nucleus in peri-nuclear vesicles. However, more thorough examinations of the
intracellular activity of Pgp and BCRP have yet to be performed.

5.7 Discussion
We have demonstrated that the plasma membrane transporter MRPl has a
sub-cellular localization from which it can promote a drug resistance phenotype.
This phenotype is reversible upon inhibition of MRPl by verapamil but
unaffected by alterations in intracellular pH. Using fluorescent markers for the
ER, the Golgi, the recycling endosomes, and the lysosomes, we have shown in the

previous chapter that this intracellular MRPl activity most likely originates fro
the lysosomes. Moreover, Pgp and BCRP also localize to lysosomal membranes
from which they also transport doxorubicin.
Of course, MRPl activity does not stem entirely from the intracellular
organelles; TMRE, for example, is effluxed by MRPl before it can accumulate in
the cell, presumably by plasma membrane localized versions of the transporter.

Strangely, the dominant activity of the protein on doxorubicin is on intracellula
membranes. Our results suggest that MRPl may have different activity profiles at
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different membranes, a difference that could be a function of
environment (lipids, cholesterol) or post-translational modifications (e.g.,
phosphorylation) that occur at some sub-cellular compartments. Alternatively,
these sub-cellular compartments may contain other transport mechanisms that act
synergistically with MRPl activity.
Intracellular localization and activity for MRPl and for other members of
the MDR transporter family may suggest different strategies for chemotherapeutic
regimens in a clinical setting. To date, inhibitors for these MDR transporters have
been selected presumably on the assumption of plasma membrane based efflux
mechanisms. MRPl-mediated intracellular drug sequestration may necessitate
alternate strategies in the search for MDR inhibitors.

Figure 5-1 Doxorubicin sequestration in M C F 7 - A d r cells, a-b. Doxorubicin is
sequestered away from the nucleus, the target of doxorubicin toxicity, into acidified
organelles in drug resistant MCF7-Adr cells (a), but not in the drug sensitive parent cell
line M C F 7 (b). c. Disrupting organellar acidification with concanamycin A, an inhibitor
of vacuolar-type proton ATPases, redistributes doxorubicin into the nucleus of M C F 7 Adr cells, suggesting the involvement of p H in drug sequestration, d. Inhibiting M R P 1
and Pgp with verapamil also redistributes doxorubicin into the nucleus of MCF7-Adr
cells, perhaps suggesting the additional involvement of these proteins in drug
sequestration, e. In M C F 7 Adr cells, doxorubicin (first micrograph) accumulates in
regions positive for the lysosomal marker synaptotagmin VII (second micrograph), an
observation m a d e clear in the merge of the two images (third micrograph).
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Figure 5-2 T h e expression of M R P 1 in drug sensitive M C F 7 cells, a-c.
The expression of M R P 1 - E C F P redistributes doxorubicin away from the
nucleus and mimics a drug resistance phenotype in this drug-sensitive M C F 7
line. d-e. A n enlarged view of M C F 7 cells expressing M R P 1 ; note the
accumulation of the drug in MRP1-positive regions of the cell (arrow).

Figure 5-3. Doxorubicin redistribution u p o n the expression of M R P L
a-c. H e L a cells transfected with the lysosomal marker synaptotagmin VII
are imaged after doxorubicin incubation. Doxorubicin accumulates in the
nucleus and, to a m u c h lesser extent, in vesicles at the periphery of the
nucleus, d-f. A close up of the cell presented in (a-c), showing doxorubicin
accumulation in peri-nuclear vesicles. These vesicles do not appear to colocalize with the lysosomal marker; however, this is just a preliminary
assessment, and the question needs further investigation, g-i. Significant
enrichment of doxorubicin occurs in the peri-nuclear region of the cell as a
result of M R P 1 - E C F P expression, and this enrichment appears to be in
regions positive for MRP1-expression.

Figure 5-4 Doxorubicin localizes to MRP1-ECFP-positive vesicles, a. E C F P
fluorescence reveals that a transiently transfected HeLa cell expresses M R P 1 both at
the plasma m e m b r a n e and in a juxtanuclear region. The scale bar is 10pm. b.
Doxorubicin fluorescence demonstrates that the drug likewise accumulates in a perinuclear region in an M R P - E C F P expressing cell, while the non-expressing cells
surrounding it accumulate the drug in the nucleus, c. The merge of M R P 1 - E C F P
fluorescence (green) and doxorubicin fluorescence (red) shows the co-localization of
doxorubicin and peri-nuclear localized M R P 1 - E C F P (yellow), d-f. A n enlarged image
of the cell depicted in (a-c) reveals individual M R P 1 - E C F P containing vesicles that
also contain doxorubicin. The scale bar is 1pm. g-i. In rare instances w h e n M R P 1 E C F P aberrantly collects in the endo-membrane system, doxorubicin accumulation is
not peri-nuclear but is likewise dispersed. The scale bar is 10pm. j-l. A cell expressing
low levels of M R P 1 - E C F P has little to no plasma m e m b r a n e E C F P fluorescence and
accumulates doxorubicin in a pattern that coincides with intracellular M R P 1 - E C F P
The scale bar is 5pm.
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Figure 5-5 Accumulation of doxorubicin in MRP1-positive regions is dependent
on M R P 1 activity, and not pH. a-b. Acridine orange staining reveals concanamycin Adependent disruption of organellar acidification. Acridine orange fluoresces red in low
p H environments. Upon the addition of concanamycin A, an inhibitor of V-type proton
ATPases, HeLa cells show significant decreases in red fluorescence (acidified
compartments), c-e. The disruption of organellar acidification with concanamycin A
has no discernable effect on the distribution of doxorubicin in M R P 1 - E C F P expressing
HeLa cells, f-h. Inhibiting M R P 1 activity with verapamil redistributes doxorubicin into
the nucleus of M R P 1 - E C F P expressing HeLa cells, and substantially reduces perinuclear accumulation of the drug. i. A non-transfected HeLa cells accumulates
doxorubicin in a pattern very similar to M R P 1 - E C F P expressing cells treated with
verapamil (f-h). There is very little perinuclear accumulation of the drug in either case.
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Figure 5-6. Crosslinking M R P 1 - E C F P interferes with its ability to
transport substrates at the plasma m e m b r a n e , as assayed by T M R E
accumulation, a-c. M R P 1 - E C F P expression prevents the intracellular
accumulation of T M R E , so that the M R P 1 positive cell is not visible under
T M R E fluorescence, d-f. Inhibiting M R P 1 with verapamil prevents M R P 1 mediated T M R E transport, and the two M R P 1 - E C F P expressing cells in this
field n o w accumulate the drug. g-i. Crosslinking cells with the cellimpermeable reagent B M [ P E O ] 4 prevents MRP1-mediated T M R E transport so
that the M R P 1 positive cell accumulates T M R E just like its non-expressing
counterparts, j-l. Addition of the cell permeable crosslinker B M H also inhibits
M R P 1 transport of T M R E . The scale bar for the micrograhps is 10pm.
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Figure 5-7 M R P 1 - E C F P actively sequesters doxorubicin in internal
compartments, a-c. Addition of the cell-impermeable cross-linker B M [ P E O ] 4 has no
effect on the sub-cellular distribution of doxorubicin in M R P 1 - E C F P expressing cells;
the drug is still to be found in peri-nuclear regions positive for M R P 1 - E C F P . d-f.
Addition of the cell-permeable crosslinker B M H redistributes doxorubicin to the
nucleus of M R P 1 - E C F P expressing cells, m u c h as the M R P 1 inhibitor verapamil does
(g-i).

Figure 5-8 T h e effect of crosslinking on the electrophoretic mobility and
transport activities of M R P 1 - E C F P . a. In an immunoblot of M R P 1 - E C F P
transfected cell lysates, an anti-MRP1 antibody recognizes a doublet w h o s e
molecular m a s s migrates below the 250kDa protein marker. However, addition of
BM[PEO]4 significantly retards the mobility of M R P 1 - E C F P . A n immunoblot of B M H
treated cells likewise reveals a changed mobility of the protein after crosslinking. b.
M R P 1 - E C F P activity can be quantified by relating h o w m u c h T M R E a cell
accumulates to h o w m u c h M R P 1 - E C F P a cell expresses. Fluorescence functions as
a reporter for both M R P 1 expression and T M R E accumulation. Neither BM[PEO]4
nor B M H increase the permeability of cells to T M R E , since all cells with background
M R P 1 fluorescence accumulate comparable levels of T M R E . Moreover, cells treated
with BM[PEO]4, regardless of the degree to which they express M R P 1 , accumulate as
m u c h T M R E as untreated, non-MRP1 expressing cells, c. M R P 1 - E C F P activity
against doxorubicin can be quantified by relating M R P 1 expression to the doxorubicin
fluorescence inside the nucleus. In BM[PEO]4 treated cells, M R P 1 - E C F P still
reduces the relative amount of doxorubicin accumulated in the nucleus. For both
BM[PEO]4 treated and untreated cells, MRP1-mediated reduction in nuclear
fluorescence is statistically significant (P< 0.01 and P<0.0001, respectively).
However, all B M H treated cells have similar amounts of doxorubicin in the nucleus,
whether they express M R P 1 - E C F P or not.
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Figure 5-9 P g p and B C R P co-localize with a lysosomal marker and
accumulate doxorubicin in regions positive for either P g p or B C R P . All scale
bars represent 10pm. a. A cell transfected with B C R P - E C F P expresses the
protein at the plasma m e m b r a n e and in intracellular regions. The image is a
deconvolved fluorescent section of a cell. b. Fluorescent dextrans chased into
the lysosomes of the cell in a accumulate in intracellular vesicles, c. The merge
of (a) and (b) shows the degree to which B C R P - E C F P (green) colocalizes with the
lysosomal marker (red), d-f. Panel shows the degree of colocalization of B C R P E C F P in (d) and doxorubicin in (e). g-i. Panel shows the degree to which PgpE C F P accumulates in intracellular vesicles (g) that are positive for fluorescent
dextrans chased into the lysosomes (h). j-l. Panel shows the localization patterns
of P g p - E C F P and doxorubicin.
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6 Chapter 6 MRPl activity and glutathione

6.1 Glutathione co-transport model
Previously published reports have suggested that MRPl-mediated
transport of chemotherapeutic agents is dependent upon the presence of reduced
glutathione. A number of lines of enquiry have suggested glutathione
involvement in MRPl activity: in vitro studies with membrane vesicles derived
from MRPl-expressing cells, in vitro transport assays with MRPl reconstituted
into proteo-liposomes, as well as whole cell drug sensitivity assays with the
glutathione-depleting agent BSO. These assays have all suggested that MRPl, a
protein belonging to an organic anion transport family, needs the organic anion
glutathione to activate the transport of hydrophobic, cationic chemotherapeutic
drugs like daunorubicin or vincristine. In their protein reconstitution studies of
MRPl, Mao et al., for example, found that glutathione stimulated the transport of
radio-labeled vincristine by over 4 fold (Mao et al, 2000). In their examination
of MRPl transfected cells, Zaman et al. observed that glutathione depletion with
BSO resulted in a significant reduction in the IC50 values of doxorubicin and
daunorubicin, 5 fold and 3 fold decreases, respectively (Zaman et al, 1995).
Glutathione has been shown to stimulate the ATPase activity of the reconstituted
protein (Hooijberg et al, 2000), and a photo-activatable derivative of glutathione,
azido-phenacyl-glutathione, photo-labels the protein specifically (Qian et al,
2002). In addition, enhanced glutathione transport has been measured in MRP1containing cells and membrane vesicles, especially in the presence of a drug
substrate.
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This data has led many to suggest a model of MRPl activity in
which reduced glutathione promotes high affinity drug binding to MRPl. Upon
binding to MRPl in the presence of glutathione, the drug is then co-transported
from the cell with glutathione. This glutathione co-transport model has been
evoked to explain MRP 1-mediated transport of the xenobiotics frequently used in
chemotherapeutic regimens. For endogenous molecules speculated to be the
physiological substrates of MRPl transport, however, the protein is not always
thought to require glutathione for its activity. LTC4, for example, has been shown
to be transported in the absence of glutathione, both in membrane vesicles and in
proteoliposomes. The conjugated estrogen derivative 17-P-Estradiol 17-(P-DGlucoronide), also a putative physiological substrate for MRPl, is also not
thought to require glutathione for its transport. These observations have led some
to speculate that reduced glutathione is necessary to activate the transport of
hydrophobic, cationic substances (Feller et al, 1995a). Indeed, the observation
that calcein, itself an MRPl substrate, does not depend on reduced glutathione for
its efflux from the cell, suggested this functional difference: glutathione activates
the transport of only those substances that are non-anionic and not conjugated to
organic anions (Feller et al, 1995a)
However, there are some problems with this assessment of MRPl activity.
Recent studies involving the conjugated estrogen estrone-3-sulfate (Qian et al,
2001), as well as a p-O-Glucuronide conjugate of 4-(Methylnitrosamino)-l-(3pyridyl)-l-butanol (NNAL) (Leslie et al, 2001), have suggested that these anion
conjugates also require glutathione for MRPl-dependent transport. In the case of
estrone3-sulfate, transport at Vmax was stimulated a little over 4 fold by the
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presence of 1 mM glutathione; in the case of NNAL-O-glucoronide,
maximal stimulation occurred at 3mM glutathione, both of which are within the
range of intracellular glutathione for the average mammalian cell, l-5mM. While
MRPl shows a glutathione requirement for estrone-3-sulfate transport (Qian et
al, 2001), the protein does not need glutathione to transport the anionic estrogen
conjugate, 17-p-Estradiol 17-(P-D-Glucoronide) (Loe et al, 1996a). Why would
MRPl require the presence of reduced glutathione to transport some conjugated
anions and not others? No model of MRPl activity to date has been able to
address this question. Moreover, in the case of those anionic conjugates that are
transported only in the presence of glutathione, no glutathione co-transport was
observed. Neither estrone-3-sulfate nor NNAL-O-glucoronide were able to
stimulate the transport of glutathione. If the glutathione co-transport model is
correct, and glutathione is being effluxed out of the cell with MRPl substrates,
then these substrates should reciprocally stimulate glutathione transport. Why
glutathione would stimulate one class of substrates in accordance with the cotransport model, and stimulate other drugs without being co-transported has not
been addressed or resolved.

6.2 Glutathione co-transport: evaluating the data
A number of other questions also arise in reviewing the model of
glutathione-dependent substrate transport. Much of the data supporting the model
has been derived from kinetic measurements of protein activity in membrane
vesicles or in proteo-liposomes. The assessment that glutathione is required for
MRPl transport of chemotherapeutic agents, for example, is based on the finding
that reduced glutathione increases transport rates several fold. However, even in
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the presence of reduced glutathione, these transport rates are
themselves quite low, and do not reflect transport rates found for other transport
proteins. Moreover, the transport rates suggested for high affinity substrates are
also extremely low and are not within a physiological range. Mao et al., for
example, report that purified MRPl reconstituted into liposomes transports its
high affinity substrate LTC4 with a Vmaxof 125 pmol/mg MRPl /min. At this
rate, one molecule of MRPl would transport one molecule of LTC4 every 42
minutes (Table 6-1). Moreover, the rate for vincristine transport in the presence
of glutathione is 19 pmol/mg MRPl/min, a rate that would correspond to one
molecule of MRPl transporting one molecule of vincristine every 4.6 hours
(Table 6-1). The rate provided for vincristine transport is not suggested to be the
maximal velocity of the protein, but it is the only one provided. These transport
rates are not comparable to the transport rates of other ATPases or even other
ABC transporters like P-glycoprotein (Table 6-2). Moreover, the rates of ATP
hydrolysis derived for purified MRPl are either also low (Table 6-3, Cole), or
correspond to non-physiological rates of substrate transport (Table 6-3 Riordan).
Transporters that couple substrate transport to ATP hydrolysis are generally
believed to transport 1 to 1,000 substrate molecules/sec. The transport rates
available for MRPl in proteoliposomes seem to suggest then that the protein
being studied has lost substantial activity during purification and reconstitution.
The transport rates provided for MRPl in membrane vesicles are more
difficult to interpret. Although each transport rate is provided at maximal velocity
(Vmax), no attempt is made to assess the total MRPl concentration in the assays.
Assessments of transport are instead provided in terms of transport velocity per
total milligram of vesicle protein (Table 6-4). Therefore, we cannot determine

Chapter 6 M R P 1 and glutathione

1qi

whether estimated transport rates could be within a physiological
range. However, if we were to estimate that MRPl protein levels in their overexpression system constitute between 0.1 and 1% of the total vesicle protein (a
conservative estimate for an over-expression system), then their transport rates
would be non-physiological for many of the substrates assayed, including those
used to invoke the glutathione co-transport model (Table 6-4).
Whole cell studies which conclude that MRPl is dependent on glutathione
for its activity are problematic, as well. For example, in their study of MRPlmediated drug resistance in SI cells over-expressing MRPl, Zaman et al. do
report a reduction in the IC50 values of both doxorubicin and daunorubicin upon
the addition of the glutathione-depleting agent BSO (Zaman et al, 1995).
However, similar reductions in the IC50 values for these two drugs were seen in
Pgp-over-expressing SI cells in the presence of BSO, and this pattern was also

evident in the SI background cell line. This discrepancy is noted in their study;
however, no attempt was made to reconcile the non-specific effects of BSO with
the model of MRPl glutathione dependence.

6.3 Methods of studying glutathione dependence in vivo
For all of these reasons, we have decided to investigate further the role of
glutathione in modulating MRPl activity, using our fluorescent model system.
Two ways of assessing glutathione dependence were available to us. The first
was to examine the effect of BSO on cells over-expressing MRPl-ECFP. The
second was to examine the effects of over-expressing MRPl on cells that had no
endogenous glutathione biosynthetic pathway. Both assays would study the effect
of glutathione depletion on MRPl activity; the former would examine the
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question pharmacologically, the latter genetically, with a cell line
generated from a mouse homozygous for a disruption in the gene encoding
y glutamylcysteine synthetase (y-GCS). The y-GCS enzyme catalyzes the first

step in glutathione synthesis (Fig. 6-1 a), and the loss of this gene product res
in the complete loss of intracellular glutathione, as determined by HPLC (Shi et
al, 2000). Although disruption of the y-GCS promoter and the first exon is
homozygous lethal in the mouse, cell lines were established from the homozygous
embryo at embryo day 3.5, five days prior to the average time of death (see Fig.
6-1 b). These cell lines could only survive in the presence of exogenously added
GSH or the reducing agent N-acetyl cysteine (NAC). Those cell lines maintained
in NAC were dubbed GCS-NAC by Shi et al, indicating both the loss of the
y-GCS gene product, as well as supplementation with NAC.
To assess the activity of MRPl in the absence of cellular glutathione, we
obtained the GCS2-NAC cell line and continued to maintain it in culture media

supplemented with NAC. To ensure that this cell line had a disruption in the gene
encoding the heavy subunit of y-GCS, we performed nested PCR on genomic
DNA isolated from GCS2-NAC, using primers suggested by Shi et al. In this
fashion, we confirmed that this cell line did contain a disruption in the y-GCS

gene (Fig. 6-2, a). Next, we wanted to ensure that this disruption would result i
the loss of glutathione production, as previously reported. For this purpose, we
employed thin layer chromotography (TLC) to detect intracellular glutathione,
using an assay commercially available from Molecular Probes. This glutathione

detection assay chemically conjugates cellular glutathione to a fluorescent probe
that can be visualized with TLC. The assay is sensitive to concentrations of
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reduced glutathione within lOuM. When samples from GCS2-NAC
cells were dotted onto the TLC plate, we found there to be no detectable

glutathione, in accordance with the previously published report (Shi et al, 2000)
(Fig. 6-2, b).

6.4 Testing human MRPl activity in mouse
Before expressing MRPl-ECFP in this glutathione null background, we
wanted to ensure that the human gene encoding MRPl would be expressed and
properly localized in a mouse embryonic stem cell line. For these sets of
experiments, we used the BDC1 cell line, a mouse cell line derived from a wildtype embryo, also at embryonic day 3.5 (Shi et al, 2000). The expression of
MRPl-ECFP in this mouse line resulted in a sub-cellular protein distribution
pattern similar to that seen in HeLa cells (see chapter 4). MRPl-ECFP localized
to the plasma membrane (Fig. 6-3, a-b), and to an intracellular region that was
predominantly perinuclear (Fig. 6-3, c-d, see also Fig. 5-2). To ensure that
MRPl-ECFP retained activity in a mouse cell line, we incubated BDC1 cells
expressing MRPl-ECFP in the MRPl substrate TMRE. Cells expressing the
protein (Fig. 6-3, e) were able to exclude the drug and were negative for TMRE

fluorescence (Fig. 6-3, f-g), indicating that the protein retained activity in th
genetic background.

6.5 MRPl is active in GCS2-NAC cells, in the absence of glutathione
We could now test the activity of MRPl-ECFP in the GCS2-NAC cell line
and thereby assess the glutathione dependence of MRP 1. We began with TMRE,

a positively-charged, MRPl substrate that is also an indicator of cell viability.
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When GCS2-NAC cells were exposed to TMRE, cells that did not
express MRPl-ECFP readily took up the drug (Fig. 6-4, a). The observation that
GCS2-NAC cells could be positive for TMRE indicates that the loss of
glutathione had not compromised cell viability. Only the cell expressing MRP1ECFP was characterized by reduced TMRE accumulation (Fig.7-4, b-c). This
MRPl-dependent reduction is made clear in a line scan of the fluorescent
intensities of the field, where red represents TMRE and green represents MRP1ECFP fluorescence (Fig. 6-4, d). The observation that MRPl-ECFP expression is
sufficient to reduce TMRE accumulation in GCS2-NAC cells suggests that MRPl

can function in the absence of glutathione on at least one of its cationic substr
The glutathione co-transport model has been evoked to explain MRPl-mediated
transport of non-anionic substrates (Feller et al, 1995b).
We next assayed the activity of MRPl against daunorubicin, a substrate
previously thought to require glutathione for its transport from the cell (Zaman
al, 1995;Renes et al, 1999). Once again, GCS2-NAC cells showed MRP1dependent daunorubicin exclusion (Fig. 6-4, e-g), and had significantly reduced

levels of intracellular daunorubicin relative to neighboring cells (Fig. 6-4, h).
These experiments suggested that MRPl did not require glutathione to transport
daunorubicin either.
Finally, we tested the activity of MRPl-ECFP against vincristine, the
substrate whose transport had been originally used to suggest the model of

glutathione co-transport. Because vincristine is not fluorescent, we assayed drug
transport by the degree to which microtubules were depolymerized after
incubation in vincristine. We have seen previously that the expression of MRPlECFP protects the cell from vincristine-induced microtubule loss (Chapter 4).

Chapter 6 M R P l and glutathione

105

When GCS2-NAC cells were incubated in vincristine, MRPl-ECFP
expression substantially mitigated the effects of the drug. MRPl-ECFP cells
retained visible microtubule structure, with the microtubule organizing center
readily identifiable (Fig. 6-4, i-k).
In order to make a more statistical appraisal of MRPl activity in the
absence of glutathione, we next quantified the accumulation of MRPl-substrates
as a function of drug fluorescence, this time using large populations of GCS2NAC cells. We found that MRPl over-expression led to a statistically significant
reduction in the accumulation of TMRE (Fig. 6-5, a) (P < 0.001). On average,
TMRE fluorescence was reduced by a little over 71% in this glutathione-deficient
cell line by the expression of MRPl-ECFP. Similarly, the expression of MRPlECFP also led to a statistically significant reduction in the accumulation of
daunorubicin in these cells (PO.001), decreasing daunorubicin fluorescence in
ECFP-positive cells by slightly over 50%. Although these fluorescence-based
assays may not correspond to direct assessments of intracellular drug
concentrations, as a result of intracellular drug metabolism or fluorescencequenching, these assays do suggest that there is a pattern of differential drug
accumulation upon MRPl-expression, and this pattern exists both in the presence
and absence of intracellular glutathione.

6.6 MRPl is active in cells pharmacologically depleted of glutathione
We next sought to investigate the glutathione dependence of MRPl in
cells treated with BSO, an irreversible inhibitor of the GCS holoenzyme. After
incubation in BSO for prolonged periods of time, the glutathione bio-synthetic
pathway is blocked and cells become depleted of their intracellular pools of
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glutathione. BSO incubation protocols typically result in 80-90%
reduction in intracellular glutathione after at least 24 hours of BSO exposure
(Mans et al, 1992). In one study in which MRPl activity was said to be
dependent upon glutathione, BSO treatment resulted in the loss of, on average,
over 82% of intracellular glutathione stores (Zaman et al, 1995). When we
incubated both HeLa and wild-type mouse embryonic stem cells in BSO
following a similar protocol (see Chapter 2), we found that glutathione stores
were likewise effected. HeLa cells, as well as BDC1 cells, experienced a greater

than 80%o reduction in intracellular glutathione after BSO treatment (Fig. 6-6 a,
b).
We next assayed MRPl activity in BSO-treated HeLa cells against both
TMRE and daunorubicin. The expression of MRPl-ECFP led to substantial
decreases in the accumulation of TMRE, whether cells were treated with BSO or
not (Fig. 6-7, compare a-d to e-h). Similarly, MRPl-ECFP expressing cells
showed substantial reductions in daunorubicin accumulation relative to

neighboring cells, despite the addition of BSO (Fig. 6-8, a-d vs. e-h). Statistic
evaluations of large populations of MRPl-expressing cells also suggested that
MRP 1 retained activity against both TMRE and daunorubicin after glutathione

depletion via BSO (Fig. 6-9). Interestingly enough, these statistical assessments
of BSO-mediated effects also suggested that BSO-treated cells accumulated more
of the MRPl substrate, independent of MRPl expression (Fig. 6-9, a and b,
compare the first two bars). TMRE and daunorubicin accumulation increased in
cells expressing background levels of MRP1-ECFP by 64.8 and 112.8%,
respectively (see Table 6-5). These results are in accordance with previously
published results demonstrating the non-MRP 1-specific effects of BSO in

Chapter 6 M R P l and glutathione

107

enhancing drug toxicity (Zaman et al, 1995). In our case, it seemed as
if BSO might be making the cell more permeable to MDR substrates like TMRE
and daunorubicin.

6.7 BSO increases cell permeability to MDR substrates
To test this possibility, we examined the effects of BSO on drug
accumulation in cells endogenously expressing varied levels of MRPl (Fig. 6-10,

a). The MCF-7 Adr cell line, for example, is multi-drug resistant, expresses both
MRPl and Pgp, and has been selected for elevated resistance to doxorubicin, an
anthracycline closely related to daunorubicin in structure. When MCF7-Adr cells
were incubated in daunorubicin, we found that these cells had significantly
elevated levels of drug accumulation in response to BSO-treatment (Fig. 6-10, b-

c). At the same light threshold levels, and under identical illumination conditio
BSO-treated cells had much greater daunorubicin fluorescence (Fig. 6-10, c) than
untreated cells (Fig.7-10, c). On average, daunorbubicin fluorescence in MCF7Adr cells increased by 181.6% as a result of BSO (Fig. 6-11, a). TMRE drug

incubation assays were more difficult to interpret in this cell line, as MCF7-Adr
cells did not uptake TMRE, perhaps indicating the toxic effects of continual
selection under doxorubicin (Fig. 6-10, d-e). We also assayed the effects of BSO
on the primary NHDF line, whose endogenous expression of MRPl was the least
elevated of the three cell lines tested (Fig. 6-10, a). When NHDF cells were
incubated in TMRE, we found that TMRE fluorescence increased on average by
179%o in response to BSO treatment (Table 7-5, Fig. 6-11, a). Finally, we
attempted to assess the effect of BSO on drug uptake in non-transfected NIH 3T3

cells, but shortly after exposure to BSO, this cell line rounded up and died (Fig
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11, c). We even examined the effect of BSO on the glutathione-null
cell line, GCS2-NAC, and discovered that in this line, too, there was a BSO

induced increase in drug accumulation (Table 7-5). Thus, in all cell lines tested
BSO had non-MRP 1 mediated effects on drug uptake and toxicity.

6.8 Discussion
Well established as an organic anion transporter with broad specificity
(Leier et al, 1994; Loe et al, 1996a; Loe et al, 1996b; Hooijberg et al, 1999),
MRPl has also been shown to transport cationic, and neutral hydrophobic
compounds like the anthracyclines, vincrisitine, and TMRE (Cole et al, 199A;
Grant et al, 1994; Paul et al, 1996; Rajagopal et al, 2002). Much speculation

has surrounded the ability of the transporter to promote the cellular efflux of n

anionic substances, and it is generally believed that compounds that are cationic
or neutral in nature are co-transported with reduced glutathione. The model for
glutathione co-transport has been suggested primarily by protein reconstitution
assays in membrane vesicles and proteoliposomes (Loe et al, 1996b; Loe et al,
1998; Mao et al, 2000; Loe et al, 2000), as well as by whole cell studies
involving glutathione depletion via BSO (Zaman et al, 1995). Glutathione is

speculated to facilitate the high affinity transport of non-anionic substances, e
by inducing conformational changes in the protein (Qian et al, 2001) or by a
mechanism that invokes positive co-operativity between drug binding and
glutathione binding (Borst et al, 1999).
When we examined the ability of MRPl to transport cationic substances in
the absence of glutathione, however, we found that MRPl still retained activity
against three of its substrates, TMRE, daunorubicin, and vincristine, substrates
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which previously were thought to require glutathione for transport. In
GCS2-NAC cells deficient in the production of y-gluatmyl cysteine synthetase, a
gene necessary for glutathione production, MRPl expression resulted in proteindependent reduction of cationic substrates. Moreover, in BSO-treated HeLa cells,
as well as in BSO-treated NHDF cells, MRPl expression also resulted in the
cellular reduction of cationic substrates. Our data is not in accord with previous
assessments of MRPl activity, and the basis for this disagreement is not clear.
However, data published to date regarding the glutathione dependence of MRPl
has been collected either in cell-free systems, in proteoliposomes or inside-out
membrane vesicles, or in BSO-treated cells depleted of cellular glutathione. In
vitro assessments of MRPl activity, though certainly indispensible for gathering
basic biochemical data, may not represent the transport abilities of the protein in
vivo. Moreover, our data indicate that when whole cells are depleted of their
glutathione stores by treatment with BSO, these cells appear to be more
permeable to MRPl substrates, an increase that cannot be explained by
glutathione depletion alone, as GCS2-NAC cells also experienced this increase
once treated with BSO.
This BSO-mediated increase in cellular drug accumulation might help
explain previously published observations that MRPl is inhibited by BSO.
Indeed, comparison of drug accumulation in MRPl-expressing HeLa cells with
and without BSO treatment (Fig. 6-9, a, bars 3-4 and Fig. 6-9, b, bars 3-4), might
lead to the conclusion of an MRPl-specific effect; however, reference to the
change in drug accumulation experienced by non-MRP 1 expressing cells (Fig. 69, a, bars 1-2, and Fig. 6-9, b, bars 1-2) makes this possibility less likely. Nonspecific increases in drug accumulation were found in all four cell lines treated
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with BSO, including GCS2-NAC cell lines. It is therefore also
difficult to conclude that BSO is increasing cell permeability by depriving
endogenous MRPl of glutathione, as GCS2-NAC cells have never biosynthesized
glutathione.
In demonstrating that MRPl can function in the absence of glutathione,
we cannot discount the possibility that, if present, glutathione does support
MRPl-mediated transport. It is entirely possible that under conditions in which
glutathione is depleted, another cellular compound functionally substitutes for
glutathione in enabling MRP 1 activity. This compound may facilitate
conformational changes in MRPl that are redox dependent or it may be cotransported with MRPl substrates. Whether another compound might be able to
functionally substitute for glutathione or whether MRPl activity is independent of
glutathione entirely should prove to be an important area of research for future
investigation.

Figure 6-1 Glutathione bio-synthetic pathway and generation of a glutathione
deficient m o u s e line. a. Glutathione biosynthesis is catalyzed by two enzymes, yglutamylcysteine synthetase (y-GCS) and glutathione synthetase. Loss of the y-GCS
enzyme or inhibition of enzyme activity via B S O results in the loss of glutathione
production. This figure is adapted from Stryer's Biochemistry, b. A m o u s e embryo
homozygous for the loss of the gene encoding the heavy subunit of y-GCS w a s
generated by Shi et al. with a disruption in the TATA box and the first exon of the gene.
The disruption w a s embryo lethal by embryo day 8.5, but cell lines were rescued at
embryo day 3.5. Arrow pairs in the figure indicate primers used to confirm the gene
disruption (see Fig. 6-2). This figure has been taken from Shi et al, 2000.
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Figure 6-2 Confirmation of the disruption in y-GCS in G C S 2 - N A C cells, a. To
confirm that the G C S 2 - N A C cells used in our experiments were deficient for glutathione
synthesis, w e performed nested P C R on genomic G C S 2 - N A C and wild type B D C 1 cells.
The primers used for the results of the P C R reaction shown here are indicated as arrow
pairs in Figure 6-1. Lanes 1, 6 are loaded with a 100 bp D N A ladder. Lane 2 is the wild
type B D C 1 g e n o m e probed with primers for the gene disruption. Lane 3 is the wild type
B D C 1 g e n o m e probed with primers for the wild-type sequence (removed by the gene
disruption in mutant allelles). Lane 4 is the mutant G C S 2 - N A C g e n o m e probed using
mutant primers. Lane 5 is the mutant G C S 2 - N A C g e n o m e probed using wild-type
primers, b. Thin layer chromotagraphy w a s performed on G C S 2 - N A C and B D C 1 cells
to confirm that the former w a s deficient in glutathione production. The assay detects
glutathione after chemical conjugation of reduced glutathione to a fluorescent substrate.
Lane 1 (box) w a s loaded with glutathione that w a s pre-conjugated to the fluorescent
substrate. Lane 2 w a s loaded with cell culture media and lysis buffer alone. Lane 3 w a s
loaded with G C S 2 - N A C cell lysates. Lane 4 w a s loaded with B D C 1 cell lysates. Sample
size of lane 4 w a s half of that of lane 3. Arrow indicates non-conjugated fluorescentsubstrate.
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Figure 6-3 M R P 1 - E C F P is expressed, properly targeted, and functional in a m o u s e
cell line. a-b. M R P 1 - E C F P is targeted to the plasma m e m b r a n e in B D C 1 m o u s e cells.
Arrows indicate the rim-staining characteristic of proteins localized to the plasma
m e m b r a n e , c-d. M R P 1 - E C F P is also found in a peri-nuclear region in B D C 1 m o u s e
cells, e-g. M R P 1 - E C F P expressing cells (e) have substantially reduced T M R E
fluorescence (f) compared to neighboring cells.
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Figure 6-4 M R P 1 is active in G C S 2 - N A C cells, a. Transiently transfected G C S 2 N A C cells incubated in T M R E showed cellular drug accumulation as a function of
rhodamine fluorescence. T h e cell in the center showed decreased T M R E
accumulation, b. A n M R P 1 - E C F P expressing cell in this s a m e field is revealed by
E C F P fluorescence, c. The merge of E C F P fluorescence (green) and rhodamine
fluorescence (red) revealed that M R P 1 expression correlated with decreased T M R E
accumulation, d. A line scan of the fluorescent intensities in the merged image (c)
illustrated MRP1-dependent T M R E reduction in these cells, e-h. M R P 1 - E C F P
transfected cells showed decreased daunorubicin accumulation as a function of
M R P 1 -expression, i-k. MRP1-expression correlated with chemo-protection against
vincristine-mediated microtubule damage.
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Figure 6-5. Quantification of M R P 1 - d e p e n d e n t drug transport in
glutathione depleted cells, a. M R P 1 - E C F P transfected G C S 2 - N A C
cells showed M R P 1 - d e p e n d e n t T M R E reduction, where cells expressing
M R P 1 are identified by "above background" E C F P fluorescence, b.
G C S 2 - N A C cells also showed an M R P 1 -dependent reduction in
daunorubicin accumulation. T h e reduction in drug accumulation seen
with M R P 1 -expression w a s statistically significant for both T M R E and
daunorubicin, with P<0.001 in each case.
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Figure 6-6 B S O incubation depleted intracellular glutathione stores by
m o r e than 8 0 % . a. H e L a cells were assayed by T L C for intracellular
glutathione stores, both with and without treatment with B S O . Treatment with
B S O decreased glutathione stores in these cells to nearly undetectable levels,
comparable to the no cell control (compare bars 1 and 2). Glutathione levels
are presented as a percentage of non-treated HeLa cells of a fixed sample size
(bar 5). Glutathione levels decrease in non-treated samples with sample size
(bar 3, bar 4). b. B D C 1 cells were also assayed by T L C for glutathione both
with and without B S O treatment. B S O reduced glutathione levels in B D C 1 cells
(bar 4) to levels comparable to the no cell control (bar 1) or G C S 2 - N A C cells (bar
2-3). B S O had no effect on glutathione levels in G C S 2 - N A C cells (bars 2-3).
Glutathione levels are expressed as a percentage of those found in wild type
cells of a fixed sample size (bar 5).
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Figure 6-8 M R P 1 is active against daunorubicin in H e L a cells depleted of cellular
glutathione via B S O . a-d.

A n MRP1-expressing H e L a cell (b) incubated in

daunorubicin s h o w e d reduced drug accumulation c o m p a r e d to two n o n - M R P 1
expressing cells (a), a s s e e n in the m e r g e d i m a g e (c) and in the line scan (d). e-h.
B S O treated H e L a cells incubated in daunorubicin still s h o w e d M R P 1 - d e p e n d e n t
daunorubicin reduction, a reduction clear in the line scan (h) of the m e r g e d i m a g e (g).
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Figure 6-9. Quantification of M R P 1 - d e p e n d e n t drug transport in H e L a
cells depleted of glutathione via B S O . a. BSO-treated HeLa cells
transfected with M R P 1 showed MRP1-dependent T M R E reduction (bars 2 and
4), just as n o n - B S O treated HeLa cells did (bars 1 and 3). B S O treatment
increased T M R E accumulation in both M R P 1 - E C F P and n o n - M R P 1 - E C F P
expressing cells (compare bars 1 and 2) b.Both BSO-treated and non-BSO
treated H e L a cells showed an MRP1-dependent reduction in daunorubicin.
B S O addition increased cellular accumulation of daunorubicin in cells
independent of M R P 1 expression (compare bars 1 and 2).
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Figure 6-10. Evaluation of the effect of B S O on cells expressing varied
levels of M R P L a. Western blots of HeLa (lane 1), N H D F (lane 2), and M C F 7 Adr (lane 5) cell lines reveal varied degrees of endogenous M R P 1 expression,
compared to M R P 1 - E C F P transfected HeLa cells (lane 3). Similar sample sizes
were loaded. Arrows indicate position of M R P 1 . Lane 4 is a protein weight
standard, b-c. B S O increases the permeability of MCF7-Adr cells to doxorubicin;
micrographs are set to identical light threshhold values, with identical exposure
times, d-e. T h e effect of B S O on the permeability of MCF7-Adr cells to T M R E
cannot be assessed, as T M R E does not enter these cells.

Figure 6-11. B S O increases cellular drug accumulation and has cytotoxic
effects in NIH3T3 cells, a. A multidrug resistant tumor cell line (MCF7-Adr) and a
primary cell line ( N H D F ) showed BSO-dependent increases in daunorubicin
accumulation, b. N H D F cells also showed BSO-dependent increases in T M R E
accumulation, c. The cytotoxicity of B S O in NIH 3T3 cells is demonstrated by the
sudden decrease of adherent cells after B S O addition.
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Table 6-1
Putative

Proteoliposomes

Substrate

(pmol/mg M R P l /min)

LTC4

Vmax

VCR* + GSH

Time for 1 protein to transport 1
substrate molecule

125

42 minutes

19

4.6 hours

V C R alone

5

17.5 hours

G S H alone

30

2.9 hours

GSH* + VCR

60

1.67 hours

Table 6-2
Transporter

Vmax of ATPase

A T P hydrolyzed/sec

(nmol /mg/min)
Na+/K+ ATPase

800 (Bear)

Ca2+ ATPase

600 (Bear)

100.0

Glucose transporter
P-glycoprotein:
unstimulated
stimulated by drug

CFTR

Substrate turn over rates
(substrate/sec)
Na+ :

5 0 0 (Hille)

Ca2+:

2 0 0 (Hille)

Glucose: 10,000 (Hille)

(Ramachandra)
1000
6500
50-250 (Bear)

2.83
18.44
1.4

Vinblastine: 1.1 ( A m b u d k a r )

1.0

Ambudkar.S.V., Cardarelli.C.O., Pashinsky.l., Stein.W.D. (1997). Relation between the turnover number for vinblastine
transport and for vinblastine-stimulated ATP hydrolysis by human P-glycoprotein. J.Biol.Chem. 272, 21160-21166.
Hille, B. Ion Channels of Excitable Membranes. Sinauer Associates, 2001.

Li,C, Ramjeesingh.M., Wang.W., Garami.E., Hewryk.M., Lee.D., Rommens.J.M., Galley.K., Bear.C.E. (1996). AT
activity of the cystic fibrosis transmembrane conductance regulator. Journal of Biological Chemistry 271, 28463-28468.

Mao.Q., Deeley.R.G, Cole,S.P. (2000). Functional reconstitution of substrate transport by purified multidr
protein MRP1 (ABCC1) in phospholipid vesicles. Journal of Biological Chemistry 275, 34166-34172.
Ramachandra.M., Ambudkar.S.V., Chen.D., Hrycyna.C.A., Dey.S., Gottesman.M.M., Pastan.l. (1998). Human Pglycoprotein exhibits reduced affinity for substrates during a catalytic transition state. Biochemistry 37, 5010-5019.

Table

6-5

Cell Type

[GSH] after
BSO
treatment

MRPl-mediated

MRPl-mediated

drug reduction (%)

drug reduction in
B S O treated cells

TMRE

Daun

TMRE
NT
65.3
71.1

Gcs-Nac
HeLa

Non-detectable

71.2

Non-detectable

84.8

51.0
87.4

NHDF

Non-detectable

78.9

84.5

Daun

increase in drug
uptake upon B S O
treatment (%)

TMRE

Daun

26.0

NT

49.9
48.3

64.8

28.5
112.8

179.0

46.6
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Chapter 7 Conclusion

In the previous chapters, we have presented an in vivo examination of
MRPl activity which has, for the first time, investigated the role of the
localization, substrate specificity, and co-factor dependence of MRPl on a single
cell basis. With the construction of our fluorescent MRPl-EGFP reporter, we
have been able to address specific questions about the effects of expressing the
protein in living cells, without the use of drug selection. In the absence of drug
selection, our model system has avoided up-regulating other drug response
mechanisms whose contributions to drug resistance might easily be conflated with
the activity of MRPl. In this way, we have been able to examine the effect of
expressing only MRPl under different conditions: when using different cell lines
or when using different putative substrates, in the absence of glutathione or in the
presence of BSO. Our model system also allowed us to examine the effect of
expressing other MDR-conferring proteins, either singly or pairs of them together,
in the same cellular background and under the same culture conditions, and thus
enabled more careful comparisons of the activity profiles of these proteins.
Finally, the use of a fluorescent construct in single-cell assays allowed us to
correlate degrees of protein expression to transport efficiencies on a cell per cell
basis, an ability important for understanding thresholds of protein activity.
This single cell approach was especially useful in studying the sub-cellular
localization and activity of MRPl. Using this technique, we were able to discern
differences in the sub-cellular distribution of MRPl in single cells expressing
different levels of the protein. We saw cells for which the protein was
predominantly in sub-cellular compartments, and cells for which the protein was
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also significantly expressed at the plasma membrane. Using
fluorescent markers for sub-cellular organelles, we were then able to identify
MRPl-positive compartments during one stage in the trafficking history of the
protein, and we were able to extend this localization to other multi-drug resistance
proteins. Furthermore, we were able to correlate the sub-cellular expression of
these proteins with patterns of drug accumulation, a task out of the range of other
detection techniques (radio-labeled transport studies, immunocytochemistry and
protocols requiring cell fixation). And, more importantly, with the use of crosslinking reagents, we were able to show, on a single cell level, that the activity
from these sub-cellular compartments was sufficient to mimic a drug resistance
phenotype.

Our model system was also useful in examining the dependence of MRPl
activity on glutathione. We were able to compare the activity profiles of the
protein in cell lines depleted for glutathione with cells whose glutathione
biosynthesis pathways were not disrupted. Single-cell examinations of
transfected cells incubated in BSO revealed to us that the addition of this
glutathione depleting agent increased cell permeability to MDR substrates. We
saw that this BSO-mediated increase was independent of MRPl activity, as
GCS2-NAC cells genetically depleted of their glutathione stores also had
increased cell permeability to MDR drugs upon BSO addition. These direct, side
by side comparisons of cells both over-expressing and not over-expressing MRPl,
of cells both treated and not treated with BSO, facilitated a more direct
examination of MRPl dependence upon glutathione. As a result, we have seen
that in multiple cell lines, and with different modes of disrupting glutathione
synthesis, MRPl retains activity in the absence of glutathione.
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This assessment of glutathione independence for MRPl runs
counter to many previously published examinations of MRPl activity, and we
have no ready explanation for this disagreement. It is possible that in the absence
of glutathione, the cell employs other organic anions to catalyze MRPl-mediated
transport. There are reports, for example, that opthalmic acid can functionally
substitute for glutathione in this capacity (Leslie et al, 2001). It is also possible
that the in vitro activity of MRPl, as revealed by protein reconstitution studies
and membrane vesicle transport assays, is not representative of the activity of the
protein in whole cells. In the process of purifying and reconstituting the protein,
for example, MRPl may have lost some of its activity; certainly, the transport
rates reported for the protein would be consistent with this hypothesis.
Other interesting avenues of investigation also remain open at the end of
this study. It has not been determined, for example, whether the functional reexpression of the GCS holoenzyme would affect MRPl-mediated transport in
GCS2-NAC cells. We are of the opinion that any changes in MRPl activity
would be attributable to enhanced cell viability in the presence of glutathione.
However, these questions could be tested by using another MDR protein like
BCRP in conjunction with MRPl. Additionally, it would be interesting to
determine whether in GCS2-NAC cells, MRPl could transport conjugated organic
anions, especially those conjugated anions that were previously thought to require
glutathione for transport. Thus far, we have only tested the transport of cationic,
hydrophobic substances like TMRE and daunorubicin in this cell line.
Conjugated organic anions like estrone-3-sulfate nor NNAL-O-glucoronide may
respond differently in this background. It might also be interesting to examine
patterns of doxorubicin sequestration in these glutathione deficient cells, and test
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whether glutathione could play any role in the metabolism or vesicular
accumulation of the drug.
A number of questions are yet to be addressed with respect to the subcellular localization and activity of MRPl, too. We have seen that in one period
in its trafficking history, the protein resides in the lyososomal compartment.
What secretory path does the protein follow to arrive at this compartment? Has
lysosomal MRPl recently been endocytosed from the plasma membrane or has it
followed the alternate ER-to-Golgi path to the lysosomes? Are there, then, two
separate pools of the protein, one directed to the plasma membrane, and another
to the lysosomes? Are there post-translational differences in these two pools or
any other discernable method of segregating them? If there is only one pool of
MRPl in these cells, is the lysosomal pool derived from recently endocytosed
plasma membrane MRPl or is the plasma membrane MRPl derived from recently
exocytosed lysosomal MRP 1 ? And with respect to the pool of lysosomal MRP 1,

does the protein reside in multi-vesicular bodies within the compartment or is th
protein capable of halting the multi-vesicularization associated with lysosomal
degradation?
We have seen that when MRPl-ECFP is weakly expressed in HeLa cells,
MRPl is to be found primarily in sub-cellular compartments, and not at the
plasma membrane at all. Is this sub-cellular MRPl also lysosomal or could it
simply be protein associated with the Golgi or the ER? Moreover, we have only
identified the sub-cellular compartment in one period in the trafficking history
the protein. Is the protein found predominantly in other sub-cellular
compartments at other times? And is this trafficking history shared with other
members of the MRP family? The apically-localized MRP2, for instance, has

v^uuciumuu

137

been found to reside in a novel sub-cellular organelle in non-polarized
hepatic cells (Tuma et al, 2002); to what extent would the baso-laterally localized
MRPl also be found there if expressed in these cells? How much of the subcellular trafficking history of MRPl is dependent upon cell and tissue type?
Would the distribution of sub-cellular MRPl be dependent upon polarization?
And in tissues, would protracted drug exposure have any effect on the localization
of the protein?
Questions also arise with respect to protein localization and doxorubicin
resistance. It has been suggested, for example, that doxorubicin resistance in
human MRPl is dependent upon a specific residue in the protein (glutamate at
amino acid 1089). Mutations in MRPl at this residue sensitize otherwise resistant
cells to doxorubicin, and the mouse ortholog, mrpl, which does not confer
resistance to doxorubicin, also does not contain glutamate in the orthologous
position. Moreover, mutations in mouse mrpl that result in glutamate
conversions at this critical residue confer doxorubicin resistance (Zhang et al,
2001). It would be interesting to see whether this residue, and patterns of
doxorubicin resistance, are linked in any way to MRPl targeting and sub-cellular
localization. If drug sequestration is an important means of conferring MRPlmediated resistance to doxorubicin, maybe residues in this region relay protein
targeting information. Perhaps there are differences in the sub-cellular
localization of mouse mrpl and human MRPl that affect drug sensitivity.
Of course, there are a host of other problems and questions not directly
addressed by the work presented in this thesis, such as the function of the protein
in normal physiology, and the many changes that must occur, both in promoter
regulation, and in protein trafficking, as a result of cellular transformation and
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acquired drug resistance in whole organisms. Much work also remains
to be done in the field addressing effective means of inhibiting MRPl-mediated
drug resistance in a clinical setting. In all, the work presented in this thesis has
addressed questions about MRPl trafficking and activity, substrate specificity and
co-factor dependence, and has at the same time, served to elicit many more and
interesting questions along the way.
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